CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS

Abstract: The present invention provides compounds which are agonists of the progesterone receptor and have structures (I) or (II) wherein R1 and R2 are independent substituents selected from the group of H, optionally substituted C1 to C6 alkyl, alkenyl, alkynyl, or alkynyl groups C3 to C8 cycloalkyl, aryl, substituted aryl, or heterocyclic groups, or COR<A> or NR<B>COR<A>; or R<1> and R<2> are fused to form an optionally substituted 3 to 8 membered Spiro cyclic alkyl or alkenyl ring or a Spiro cyclic ring containing one to three heteroatoms selected from O, S and N; R<A> is selected from H, amino, or optionally substituted C1 to C3 alkyl, aryl, C1 to C3 alkoxy, or C1 to C3 aminoalkyl groups; R<B> is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl; R<3> is H, OH, NH2 COR<C>, or optionally substituted C1 to C6 alkyl, C3 to C6 alkenyl, or alkynyl groups; R<C> is selected from H or optionally substituted C1 to C3 alkyl, aryl, C1 to C3 alkoxy, or C1 to C3 aminoalkyl groups; Q<1> is S, NR<7>; or CR<8>R<9>, R<5> is an optionally trisubstituted benzene ring or an optionally substituted five or six membered heterocyclic ring with 1, 2, or 3 ring heteroatoms selected from the group of O, S, SO, SO2 or NR<6>; or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds for contraception and the treatment of progesterone-related maladies.

Description: CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS Field of the Invention This invention relates to compounds which are agonists of the progesterone receptor, their preparation and utility This invention also provides methods of using these compounds in the inducement of contraception and the treatment and/or prevention of dysfunctional bleeding, uterine leiomyomata, endometnosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the endometπum, ovary, breast, colon, and prostate Backeround of the Invention Intracellular receptors (IR) form a class of structurally related gene regulators known as "ligand dependent transcription factors" (R M Evans, Science, 240, 889, 1988) The steroid receptor family is a subset of the IR family, including progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR) The natural hormone, or ligand, for the PR is the steroid progesterone, but synthetic compounds, such as medroxyprogesterone acetate or levonorgestrel, have been made which also serve as ligands Once a ligand is present in the fluid surrounding a cell, it passes through the membrane via passive diflfusion, and binds to the IR to create a receptor/hgand complex This complex binds to specific gene promoters present in the cell's DNA Once bound to the DNA the complex modulates the production of mRNA and protein encoded by that gene A compound that binds to an IR and mimics the action of the natural hormone is termed an agonist, whilst a compound which inhibits the effect of the hormone is an antagonist PR agonists (natural and synthetic) are known to play an important role in the health of women PR agonists are used in birth control formulations, typically in the presence of an ER agonist, alternatively they may be used in conjunction with a PR antagonist ER agonists are used to treat the symptoms of menopause, but have been associated with a proliferative effect on the uterus which can lead to an increased nsk of uterine cancers Co-administration of a PR agonist reduces/ablates that nsk The compounds of this invention have been shown to act as competitive inhibitors of progesterone binding to the PR and act as agonists in functional models, either/or in-vitro and in-vivo These compounds may be used for contraception, in the treatment of fibroids, endometnosis, breast, uterine, ovaπan and prostate cancer, and post menopausal hormone replacement therapy Jones, et al descπbe in U S Patent No 5,688,810 the PR antagonist dihydroquinoline 1 Jones, et al, described the enol ether 2 (U S Patent No 5,693,646) as a PR ligand Jones, et al, descπbed compound 3 (U S Patent No 5,696,127) as a PR ligand Zhi, et al, described lactones 4, 5 and 6 as PR antagonists (J Med Chem , 41, 291, 1998) Zhi, et al, descπbed the ether 7 as a PR antagonist (J Med Chem., 41, 291, 1998) Combs, et al , disclosed the amide 8 as a hgand for the PR (J Med Chem , 38, 4880, 1995) Perlman, et al , descπbed the vitamin D analog 9 as a PR ligand (7et Letters, 35. 2295, 1994) Hamann, et al, descπbed the PR antagonist 10 (Ann -V Y Acad Sci , 761, 383, 1995) Chen, et al, descπbed the PR antagonist 11 (Chen, et al, POI-37, 16 th Int Cong Het Chem , Montana, 1997) 11 Kuπhaπ, et al , descπbed the PR hgand 12 (J Antibiotics, 50, 360, 1997) 12 Sakata et al (JP 07159917, CA 123 301431) teach that certain benzoxazιn-2- thione compounds such as compound A can be used as photographic materials Kim et al disclose that some imidazole substituted benzothiazines, such as compound B, can be used as cardiotomcs (U S Patent No 5,171,851 and EP 510235) More recently, Young et al (WO95/20389) and Christ et al (WO98/14436) claimed benzoxazιn-2-thιones such as compound C as inhibitors of HIV reverse transcπptase Pflegel et al (Pharmazie, 37(10), 714-717(1982)) disclosed quιnazolιn-2- thiones such as compound D in their study of polarography of heterocyclics, but disclosed no activity for compound D Description of the Invention This invention provides compounds of the formula wherein Ri and R> are independent substituents selected from the group of H, G to C 6 alkyl, substituted Ci to C 6 alkyl, C 2 to C 6 alkenyl, substituted C 2 to C 6 alkenyl, C 2 to C 6 alkynyl, substituted C 2 to C 6 alkynyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, COR A , or NR B COR A , or R 1 and R 2 are fused to form a spirocyclic ring selected from a), b) or c), below, each spirocyclic ring being optionally substituted by from 1 to 3 substituents selected from H or Q -C 3 alkyl a) a 3 to 8 membered spirocyclic alkyl ring, preferably a 3 to 6 membered spirocyclic alkyl ring, or b) a 3 to 8 membered spirocyclic alkenyl ring, preferably a 3 to 6 membered spirocyclic alkenyl ring, or c) a 3 to 8 membered spirocyclic ring containing one to three heteroatoms selected from O, S and N, preferably a 3 to 6 membered spirocyclic rmg containing one to three heteroatoms, R A is selected from H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, G to C 3 alkoxy, substituted Ci to C 3 alkoxy. amino, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl, R B is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl, R 3 is H, OH, NH 2 , C, to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 6 alkenyl, substituted Ci to C 6 alkenyl, alkynyl, or substituted alkynyl, or COR c , R c is selected from H, G to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl, R 4 is selected from H, halogen, CN, N0 2 , Ci to C 6 alkyl, substituted G to C 6 alkyl, Ci to C 6 alkoxy, substituted Ci to Ce alkoxy, Ci to C 6 aminoalkyl, or substituted Ci to C 6 aminoalkyl, R 5 is selected from groups a), b), or c) below a) R 5 is a tπsubstituted benzene rmg containing the substituents X, Y and Z as shown below X is selected from the group including halogen, CN, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, G to C 3 alkoxy, substituted G to C 3 alkoxy, Ci to C 3 thioalkoxy, substituted Ci to C 3 thioalkoxy, Ci to C 3 aminoalkyl, substituted Ci to C 3 aminoalkyl, N0 2 , Ci to C 3 perfluoro alkyl, 5 or 6 membered heterocychc ring containing 1 to 3 heteroatoms, COR D , OCOR D , or NR E COR D , R D is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl, R E is H, Ci to C 3 alkyl, or substituted G to C 3 alkyl, Y and Z are independent substituents selected from the group of H, halogen, CN, N0 2 , C, to C 3 alkoxy, G to C 3 alkyl, or Q to C 3 thioalkoxy, or b) R 5 is a five or six membered heterocychc ring with 1, 2, or 3 ring heteroatoms selected from the group of O, S, S(O), S(O 2 ) or NR 6 and containing one or two independent substituents from the group of H, halogen, CN, N0 2 and Ci to C 3 alkyl, C, to C 3 alkoxy, G to C 3 aminoalkyl, COR F , or NR G COR F , R F is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl, R G is H, Ci to C 3 alkyl, or substituted C, to C 3 alkyl, R 6 is H, or Ci to C 3 alkyl, or c) or R 5 is a six membered πng with the structure wherein X 2 is halogen, CN, or NO 2 R 7 is selected from the group of CN, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to Cg cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, or substituted heterocyc c, S0 2 CF 3 , OR 11 or NR n R 12 , R 8 and R 9 are independent substituents selected from the group of H, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, N0 2 , CN, or CO 2 R 10 , R 10 is Ci to C 3 alkyl, or CR 8 R 9 comprise a six membered πng as shown by the structure below Q 2 is selected from the moieties R u , R 12 and R 13 are independently selected fromH, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl or sulfonyl, or a pharmaceutically acceptable salt thereof A preferred list of substituents represented by R u , R 12 and R 13 in groups of the compounds described herem are H, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, -C(O)- (Ci to C 6 alkyl), -S(0) 2 -(Cι to C 6 alkyl), phenyl or benzyl Among the preferred compounds of this invention are those of the formula wherein R 1 is H, Ci to C 6 alkyl, substituted C, to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocyclic, COR A , or NR B COR A , R 2 is H, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 2 to C 6 alkenyl, substituted C 2 to C 6 alkenyl, C 3 to Cg cycloalkyl, substituted C 3 to Cg cycloalkyl, aryl, substituted aryl, heterocyc c, substituted heterocychc, COR A , or NR B COR A , or R 1 and R 2 are fused to form a) a 3 to 8 membered spirocyclic alkyl πng optionally substituted by from 1 to 3 substituents selected from H or G to C 3 alkyl, or b) a 3 to 8 membered spirocyclic alkenyl πng optionally substituted by from 1 to 3 substituents selected from H or Q to C 3 alkyl, or c) a 3 to 8 membered spirocyclic πng containing one to three heteroatoms selected from the group of O, S and N, the ring being optionally substituted by from 1 to 3 substituents selected from H or Ci to C 3 alkyl, R A is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted G to C 3 aminoalkyl, R B is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl, R 3 is H, OH, NH 2 , C, to C 6 alkyl, substituted d to C 6 alkyl, C 3 to C 6 alkenyl, substituted Ci to C 6 alkenyl, alkynyl, or substituted alkynyl, or COR c , R c is H, Ci to C 4 alkyl, substituted Ci to C 4 alkyl, aryl, substituted aryl, Ci to C 4 alkoxy, substituted Ci to C 4 alkoxy, Ci to C 4 aminoalkyl, or substituted Ci to C 4 aminoalkyl, R 4 is H, halogen, CN, N0 2 , Ci to C 6 alkyl, substituted G to C 6 alkyl, Ci to C 6 alkoxy, substituted Ci to C 6 alkoxy, Ci to C 6 aminoalkyl, or substituted Ci to C 6 aminoalkyl, R 5 is a tπsubstituted benzene πng containing the substituents X, Y and Z as shown below, X is taken from the group including halogen, CN, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 thioalkoxy, substituted Ci to C 3 thioalkoxy, Ci to C 3 aminoalkyl, substituted Ci to C 3 aminoalkyl, N0 2 , Ci to C 3 perfluoroalkyl, 5 membered heterocychc πng containing 1 to 3 heteroatoms, COR D , OCOR D , or NR E COR D , R D is H, C, to C 3 alkyl, substituted C, to C 3 alkyl, aryl, substituted aryl, C, to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl, R E is H, Ci to C 3 alkyl, or substituted C, to C 3 alkyl, Y and Z are independent substituents taken from the group of H, halogen, CN, N0 2 , Ci to C 3 alkoxy, Ci to C 3 alkyl, or Ci to C 3 thioalkoxy, or R 5 is a five or six membered πng with 1, 2, or 3 heteroatoms from the group including O, S, SO, S0 2 or NR 6 and containing one or two independent substituents from the group including H, halogen, CN, N0 2 and G to C 3 alkyl, G to C 3 alkoxy, R 6 is H, or Ci to C 3 alkyl, Q 1 is S, NR 7 , CR S R 9 , R 7 is selected from CN, G to C 6 alkyl, substituted Q to C 6 alkyl, C 3 to Cg cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, S0 2 CF 3 , OR 11 or NR H R 12 , R 8 and R 9 are independent substituents from the group including H, G to C 6 alkyl, substituted G to C 6 alkyl, C 3 to Cg cycloalkyl, substituted C 3 to Cg cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocyclic, NO 2 , CN or CO 2 R 10 , R !0 is C, to C 3 alkyl, or CR 8 R 9 compπse a six membered πng as shown by the structure below Q is selected from the moieties f? 11 R 11 R 12 f? 11 — N— O-R 12 , _Jι_ | j,_ R 13 or — O— — R R 11 , R 12 and R 13 are independently selected fromH, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl or sulfonyl, or a pharmaceutically acceptable salt thereof Other preferred compounds are those of Formula I wherein R 1 and R 2 and are independently selected from the group of Ci to C 3 alkyl, substituted G to C 3 alkyl, or spirocyclic alkyl constructed by fusing R 1 and R 2 to form a 3 to 6 membered spirocyclic rmg, R 3 is H, OH, NH 2 , C, to C 6 alkyl, substituted C, to C 6 alkyl, or COR c , R c is H, Ci to C 4 alkyl, or Ci to C 4 alkoxy, R 4 is H, halogen, N0 2 , Ci to C 3 alkyl, or substituted Ci to C 3 alkyl, R 5 is a disubstituted benzene πng containing the substituents X, and Y as shown below X is selected from the group of halogen, CN, Ci to C 3 alkoxy, Ci to C 3 alkyl, NO 2 , Ci to C 3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or G to C 3 thioalkoxy, Y is a substituent selected from the group of H, halogen, CN, N0 2 , Ci to C 3 alkoxy, G to C 4 alkyl, or G to C 3 thioalkoxy, or R 5 is a five membered πng with the structure shown below R 6 is H, or C, to C 3 alkyl, or C, to C 4 C0 2 alkyl. X' is selected from the group including halogen, CN, N0 2 , G to C 3 alkyl or G to C 3 alkoxy, Y' is selected from the group of H and Ci to C 4 alkyl, or R is a six membered rmg with the structure wherei X 2 is halogen, CN, or NO 2 , Q is S, NR 7 , or CR 8 R 9 , R 7 is selected from the group of CN, Q to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, or SO 2 CF 3 , R 8 and R 9 are mdependent substituents selected from the group of H, G to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to Cg cycloalkyl, aryl. substituted aryl, heterocychc, substituted heterocychc, NO 2 , CN or CO 2 R 10 , R'° is C, to C 3 alkyl, CR 8 R 9 a six membered ring as shown by the structure below or a pharmaceutically acceptable salts thereof Further preferred compounds are those of the formula wherein R 1 and R 2 and are independently selected from the group of CH 3 and spirocychc alkyl constructed by fusing R 1 and R 2 to form a 6 membered spirocychc πng, R 3 is H, OH, NH 2 , CH 3 , substituted methyl, or COR c , R c is H, Ci to C 3 alkyl, or C, to C 4 alkoxy, R 4 is H, halogen, or Q to C 3 alkyl, R 5 is a disubstituted benzene πng containing the substituents X and Y as shown below X is selected from the group of halogen, CN, methoxy, NO 2 , or 2-thιazole, Y is a substituent selected from H and F, or R 5 is a five membered πng with the structure X is selected from the group of halogen, CN, N0 2 , Y is from the group of H and G to C alkyl, Q 1 is selected from S. NR 7 , or CR 8 R 9 , R 7 is selected from the group of CN, G to C 6 alkyl, substituted G to C 6 alkyl, C 3 to Cg cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, or S0 2 CF 3 , R and R are independent substituents selected from the group of H, Ci to C 6 alkyl, substituted G to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, N0 2 , CN or C0 2 R 10 , R 10 is Ci to C 3 alkyl, or CR 8 R 9 comprise a six membered ring of the structure below or a pharmaceutically acceptable salt thereof Another prefeπed subgroup of this invention compπses compounds of the formula wherein R 1 and R 2 and are independently selected from the group of CH 3 and spirocychc alkyl constructed by fusing R 1 and R 2 to form a 6 membered spirocyc c πng, R 3 is H, OH, NH 2 , CH 3 , substituted methyl, or COR c , R c is H, Ci to C 3 alkyl, or G to C 4 alkoxy, R 4 is H, halogen, or G to C 3 alkyl, R 5 is a disubstituted benzene πng containmg the substituents X and Y as shown below X is selected from the group of halogen, CN, methoxy, N0 2 , or 2-thιazole, Y is a substituent selected from H and F, or R 5 is a five membered ring with the structure X is selected from the group of halogen, CN, N0 2 , Y is from the group of H and G to C 4 alkyl, Q 2 is selected from the moieties _ R» s R H , R 12 and R 13 are independently selected fromH, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl or sulfonyl, or a pharmaceutically acceptable salt thereof The compounds of this invention may contain an asymmetπc carbon atom and some of the compounds of this invention may contain one or more asymmetπc centers and may thus give πse to optical isomers and diastereomers While shown without respect to the stereochemistry m Formula I, the present invention includes such optical isomers and diastereomers, as well as the racemic and resolved, enantiomerically pure R and S stereoisomers, as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof The term "alkyl" is used herein to refer to both straight- and branched-chain saturated aliphatic hydrocarbon groups havmg one to eight carbon atoms, preferably one to six carbon atoms, "alkenyl" is intended to mclude both straight- and branched- chain alkyl group with at least one carbon-carbon double bond and two to eight carbon atoms, preferably one to six carbon atoms, "alkynyl" group is intended to cover both straight- and branched-chain alkyl group with at least one carbon-carbon tπple bond and two to eight carbon atoms, preferably two to six carbon atoms The terms "substituted alkyl", "substituted alkenyl", and "substituted alkynyl" refer to alkyl, alkenyl, and alkynyl as just descπbed having one or more substituents from the group including halogen, CN, OH, N0 2 , ammo, aryl, heterocychc, substituted aryl, substituted heterocychc, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, arylthio These substituents may be attached to any carbon of alkyl, alkenyl, or alkynyl group provided that the attachment constitutes a stable chemical moiety The term "aryl" is used herein to refer to an aromatic system which may be a single rmg or multiple aromatic πngs fused or linked together as such that at least one part of the fused or linked rings forms the conjugated aromatic system The aryl groups include, but are not limited to, phenyl, naphthyl, biphenyl, anthryl, tetrahydronaphthyl, phenanthryl The term "substituted aryl" refers to aryl as just defined having one to four substituents from the group including halogen, CN, OH, N0 2 , amino, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy. alkylamino, or arylthio The term "heterocychc" is used herem to descπbe a stable 4- to 7-membered monocychc or a stable multicyc c heterocyclic ring which is saturated, partially unsaturated, or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group including N, O, and S atoms The N and S atoms may be oxidized The heterocychc πng also includes any multicychc πng m which any of above defined heterocyc c πngs is fused to an aryl rmg The heterocychc rmg may be attached at any heteroatom or carbon atom provided the resultant structure is chemically stable Such heterocychc groups mclude, for example, tetrahydrofuran, p peπdinyl, piperazinyl, 2- oxopipeπdinyl, azepmyl, pyrrohdinyl, lmidazolyl, pyridyl, pyrazinyl, pynmidinyl, pyndazinyl, oxazolyl, isoxazolyl, morpho nyl, indolyl, quinolinyl, thienyl, furyl, benzofuranyl, benzothienyl, thiamorpholinyl, thiamo hohnyl sulfoxide, and isoqumohnyl The term "substituted heterocychc" is used herem to describe the heterocychc just defined havmg one or more substituents selected from the group which mcludes halogen, CN, OH, N0 , ammo, alkyl, substituted alkyl, cycloalkyl, alkenyl, substituted alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio The term "alkoxy" is used herem to refer to the OR group, where R is alkyl or substituted alkyl The term "aryloxy" is used herem to refer to the OR group, where R is aryl or substituted aryl The term "alkylcarbonyl" is used herem to refer to the RCO group, where R is alkyl or substituted alkyl The term "alkylcarboxy" is used herem to refer to the COOR group, where R is alkyl or substituted alkyl The term "ammoalkyl" refers to both secondary and tertiary amines wherem the alkyl or substituted alkyl groups, containmg one to eight carbon atoms, which may be either same or different and the point of attachment is on the nitrogen atom The term "halogen" refers to Cl, Br, F, and I elements The compounds of this mvention can be prepared following the Schemes illustrated below Scheme 1 As demonstrated m Scheme I, the compounds of this mvention are generally prepared by employmg the suitable coupling reaction as a final step An appropπately substituted ortho-ammo benzoic acid or its deπvatives such as ethyl ester (X = Br, I, Cl, or a latent couplmg precursor such as alkoxy group which can be converted mto a OTf group suitable in the couplmg reaction) was treated with a suitable organo metallic reagent, e g Grignard reagent, m appropnate nonprotic solvents which mclude, but are not limited to, THF or ether to give ortho-ammo carbinol 2 under an mert atmosphere such as argon or nitrogen at -78 °C to room temperature Rmg closure of carbinol 2 to yield benzoxazιn-2-ones 3 is commonly effected by a condensing agent such as carbonyldiimidazole, phosgene, dimethylcarbonate, or diethylcarbonate m a suitable nonprotic solvent such as THF at temperatures ranging from room temperature to 65 °C The arylation of benzoxazm-2-ones 3 to yield 4 can be effected by vanous couplmg reactions mcludmg Suzuki, Stille reactions These reactions are commonly performed m the presence of transition metallic catalyst, e g , palladium or nickel complex often with phosphmo hgands, e g , Ph 3 P, dppf, dppe or palladium acetate Under this catalytic condition, an appropπately substituted nucleophilic reagent, e g , aryl boromc acid, arylstannane, or aryl zinc compound, is coupled with benzoxazmones 3 to give 4 If a base is needed m the reaction, the commonly used bases mclude, but are not limited to, sodium bicarbonate, sodium carbonate, potassium phosphate, baπum carbonate, or potassium acetate The most commonly used solvents m these reactions mclude benzene, DMF, isopropanol, ethanol, DME, ether, acetone, or a mixture of above solvents and water The coupling reaction is generally executed under an mert atmosphere such as mtrogen or argon at temperatures ranging from room temperature to 95 °C Benzoxazmones 3 can be converted mto a nucleophile such as boromc acid which can be coupled with an appropnate electrophile, e g , aryl bromide or aryl iodide, to yield 4 employing the couplmg reaction condition as descπbed above The transformation of 3 mto 5 can be effected by treatmg 3 with an organo metallic reagent, e g , n-BuLi, m a nonprotic solvent such as THF or ether followed by quenching the reaction solution with a suitable electrophile, such as tπmethyl borate, tπisopropyl borate, or zinc chloride at temperatures ranging from -78 °C to room temperature under an mert atmosphere such as argon or nitrogen Scheme 1a Scheme la illustrates an alternative approach leading to the benzoxazmones 3 Thus, an appropriate aniline 1 is protected with a suitable alkoxy carbonyl protective group mcludmg but not hmited to allenoxy carbonyl, t-butoxy carbonyl, benzoxy carbonyl, ethoxy carbonyl, or methoxy carbonyl m a suitable solvent such as THF, acetomtπle, with or without presence of a base either as a catalyst or as an acid scavenger The protected anihne is then treated with a suitable organo metallic reagent such as organo lithium agent or Gπgnard reagent in the same fashion as to prepare compound 2 to give the carbmol 6 The treatment of 2a with a suitable base such as potassium t-butoxide, n-butyl lithium, potassium hydroxide m an appropnate solvent such as toluene, THF, alcohol under an mert atmosphere such as nitrogen or argon at the temperature ranging from room temperature to the boiling pomt of the relevant solvent to afford benzoxazmones 3 Scheme II describes the procedures to prepare benzoxazmones beaπng two different substituents at posιtιon-4 The Weinreb amide 8 can be prepared from an appropπately substituted isatoic anhydπde 7 when treated with N-, O- d-methylhydroxyl-amme hydrochloπde salt m a protic solvent such as ethanol, isopropanol at reflux under an mert atmosphere such as argon or mtrogen Couplmg of amide 8 with an aryl electrophile such as aryl boromc acid or arylstaimane to give 9 can be effected by employing a typical couplmg reaction such as Suzuki, Stille couplmg procedure m a similar fashion as descπbed for the preparation of benzoxazinones 4. Treatment of Weinreb amide 9 with organo metalhc compounds, e.g., alkyllithium, alkynyllithium, arylhthium, or their Grignard counterpart in a nonprotic solvent such as THF or ether under an inert atmosphere such as argon or nitrogen at -78 °C to room temperature affords amino ketone 10. Conversion of ketone 10 to carbinol 11 can be effected by treatment of 10 with an organo metalhc reagent such as alkyl, alkynyl, or aryl Grignard compound in a nonprotic solvent such as THF or ether under an inert atmosphere such as argon or nitrogen at -78 °C to room temperature. Conversion of ketone 10 to carbinol 11 can also be effected by reduction of ketone group of 10 to the carbinol moiety of 11 using an appropriate reducing reagent such as hthium aluminum hydride, sodium borohydride in a suitable solvent such as THF, ether, or anhydrous alcohol under an inert atmosphere in the temperature range from 0 °C to the boiling point of the solvent. Ring closure of carbinol 11 to produce the compounds of this invention can be accomphshed with condensing agents such as carbonyldiimidazole, phosgene, dimethylcarbonate, or diethylcarbonate in a suitable nonprotic solvent such as THF at temperatures ranging from room temperature to 65 °C. Scheme π ArB(OH)2,Pd(Ph3P)4NaC03 DME/H20,85 degreees C, N2 R fi Lι or R 6 MgX, THF, -78 degreees C to r R- 7 -vϊgX, -78 degrees C to rt, NL CDI or tnphosgene, THF, 0 degrees C to 65 degrees C , 12 Alternatively, ortho-ammo ketone 10 can be prepared by treatment of ortho - ammo benzonitπle 14 with an organo metalhc compound such as organo hthium reagent or Gnngard reagent m a suitable solvent such as THF or ether under an mert atmosphere such as argon or nitrogen at temperatures ranging from -78 °C to room temperature as illustrated in Scheme III Benzonitnle 14 can be readily prepared from an appropnately substituted benzonitnle such as bromobenzonitπle 13 usmg a suitable coupling reaction such as Stille or Suzuki protocol earned out m a similar fashion as described for the preparation of the Weinreb amide 9 Scheme III RgLi or R 6 MgX, 0 degrees C. Scheme IV depicts an approach to prepare benzoxazmones with a low perfluoroalkyl substituent at posιtιon-4, e g Re is tnfluoromethyl group An appropπately substituted chloroanihne 15 was protected with a suitable protective group such as pivaloyl chloπde or di-tert-butyl pyrocarbonate to give protected aniline 16 m a suitable solvent such as acetomtπle, acetone, THF, methylene chloride, or a mixture of solvent such as methylene chloride and water under an mert atmosphere such as argon or mtrogen at temperatures ranging from 0 °C to 70 °C A suitable base such as sodium carbonate, sodium bicarbonate, or potassium carbonate may be needed when the reaction produces an acid as a side-product such as hydrochlonde Treatment of 16 with an appropriate alkylhthium such as rz-butylhthium or s-butylhthium followed by reaction with a low perfluorocarboxy derivatives, e g , tπfluoroacetyl chloride, 1- (tπfluoroacetyl)- imidazole, or ethyl tr fluoroacetate m a nonprotic solvent such as ether or THF under an mert atmosphere such as argon or nitrogen at -78 °C to ambient temperature gives the protective ortho-ammo ketones Subsequent removal of the protectmg group can be effected by reaction of protected ammo ketones with a suitable acid such as TFA, 3N aqueous hydrochlonde solution m a suitable solvent such as methylene chlonde or water at 0 °C to boiling pomt of the solvent to afford ortho-ammo ketone 17 Scheme IV (1) w-BuLi, THF, -78 degrees C to 0 degrees C ReCOX, N2 (2) 3N HC1, H20, N2, reflux R 7 Lι or R 7 MgX, THF, -78 degrees C to rt CDI or tπphosgene, THF, 0 degrees C to 65 degrees C ArB(OH)2, Nι(dppf)C12, K3P04 dioxane, 85 degrees C, N2 12 The preparation of 6-chlorobenzoxazmones 19 from 17 can be accomplished in the same fashion as descπbed for the synthesis of benzoxazmone 12 from ketone 10 Couplmg of 19 with an aryl group to yield 12 can be effected by a nickel complex catalyzed couplmg reaction The palladium catalysts proved not to be an efficient catalyst m this couplmg process The couplmg reaction of 19 with an appropnate aryl boromc acid can be accomplished m the presence of a suitable base such as potassium phosphate and a catalyst of nickel (0 or II) complex, e g a mckel complex of 1,2- bιs(dιphenylphosphιno)ethane, l,r-bιs(dιphenylphosphmo)feπocene, or tnphenylphosphine The most commonly used solvents m the reaction mclude dioxane or THF The couplmg reaction is generally executed under an mert atmosphere such as nitrogen or argon at temperatures ranging from ambient temperature to 95 °C As descπbed m Scheme V the conversion of benzoxazιn-2-ones 3 or 12 mto benzoxazιn-2-thιones 20 or 21 can be accomphshed by treatment of 3 or 12 with a suitable sulfur reagent such as Lawesson's reagent m a nonprotic solvent such as o- xylene, chlorobenzene, or toluene under an mert atmosphere such as argon or nitrogen at reflux Scheme V Lawesson's reagent, O-xylene reflux, N2 20 Lawesson's reagent, O-xylene reflux, N2 12 21 Schemes VI and VII descnbe the synthesis of other benzoxazmone bioisosteres Using a similar procedure reported by Kondo et al (Kondo, et al J Med Chem 33(7), 2012-2015 (1990)) compound 22 can be formed by treatment of ammo carbmol 11 with an appropnate ketene-S, S-acetals (at least one of Rι 6 or R ]7 is an electron withdrawmg group) in a suitable solvent such as toluene or anhydrous ethanol under an mert atmosphere such as nitrogen or argon at reflux In a similar fashion, compound 23 can be formed by reaction of ammo carbmol 11 with an appropnate lmino-S, S-acetals or lmino-acetals (R ]g is an electron withdrawmg group) employing a procedure similar to that of Evers, et al (Evers, et al / Prakt Chem 333(5), 699-710 (1991)) or Haake et al (Haake et al Synthesis-Stuttgart 9, 753-758 (1991)) in a suitable solvent such as ethanol under an mert atmosphere such as argon or nitrogen at reflux Other procedures (e g Wrobel et al J Med Chem 32, 2493(1989)) potentially leading to compounds 22 or 23 from 20 or 21 is illustrated in scheme Vila Thus, compound 20 or 21 is alkylated with an appropnate alkylating agent such as the Meerwein reagent m a suitable solvent such as methylene chlonde This is then followed by a nucleophihc replacement of an appropnate nucleophile such as carbon anion or a amme base to give compounds 22 or 23, which may produce either tautomeπc form of compounds 22 or 23 Scheme VI 22 Scheme VH 23 Scheme VHa 20 or 21 Specific Examples As illustrated in Scheme VIII, the compound 21 can be further derivatized at position- 1 via numerous approaches leading to a variety of the novel cyclothiocarbamate derivatives including 1 -alkyl, substituted 1 -alkyl, 1 -carbonyl, substituted 1 -carbonyl, 1-carboxy, substituted 1-carboxy derivatives. For example, alkyl or substituted alkyl derivatives 24 can be formed by treatment of thiocarbamate 12 or 6 with a suitable base such as sodium hydride in suitable solvent such as DMF under an inert atmosphere, such as argon or nitrogen, followed by addition of an appropriate electrophile such as alkyl or substituted alkyl bromide, iodide, or triflate. Such a transformation of 21 at position- 1 can also be effected using a biphasic condition as indicated in Scheme VIII in which alkylation is executed using a biphasic catalyst such as tributylammonium bromide in a suitable solvent such as acetonitrile. A further example of such a modification includes, but is not limited to, heating 21 with triethyl orthoformate to afford 1 -substituted derivatives 24. (Scheme VIII) The acylation or carboxylation of the compound 21 at position- 1 to give compound 25 can be readily effected by treatment of 12 or 6 with a suitable acylating or carboxylating reagent such as di-t-butyl dicarbonate in the presence of a suitable basic catalyst such as DMAP in a suitable solvent such as acetonitrile under an inert atmosphere such as argon or nitrogen. The amination of position- 1 of compound 21 to give compound 26 can be furnished usmg a suitable aminating reagent such as chloroamine m the presence of a suitable base such as sodium hydride in a suitable solvent such as THF or diethyl ether following the literature procedure (Metlesics et al J Org Chem 30, 1311(1965)) Scheme Vffl 25 26 The compounds of the present mvention can be used in the form of salts denved from pharmaceutically or physiologically acceptable acids or bases These salts mclude, but are not hmited to, the following salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoπc acid and, as the case may be, such orgamc acids as acetic acid, oxalic acid, succinic acid, and maleic acid Other salts mclude salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium m the form of esters, carbamates and other conventional "pro-drug" forms, which, when admmistered m such form, convert to the active moiety in vivo This mvention mcludes pharmaceutical compositions and treatments which comprise administeπng to a mammal a pharmaceutically effective amount of one or more compounds as described above as agonists of the progesterone receptor The progesterone receptor agomsts of this mvention, used alone or m combination, can be utilized in methods of contraception and the treatment and/or prevention of dysfunctional bleedmg, uterine leiomyomata, endometnosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the endometnum, ovary, breast, colon, and prostate Additional uses of the mvention mclude stimulation of food intake This mvention also mcludes pharmaceutical compositions utilizing the compounds herein, preferably in combination with a pharmaceutically acceptable carrier or excipient When the compounds are employed for the above utihties, they may be combmed with one or more pharmaceutically acceptable earners or excipients, for example, solvents, diluents and the hke, and may be administered orally m such forms as tablets, capsules, dispersible powders, granules, or suspensions containmg, for example, from about 0 05 to 5% of suspending agent, syrups containmg, for example, from about 10 to 50% of sugar, and elixirs containmg, for example, from about 20 to 50% ethanol, and the like, or parenterally m the form of sterile mjectable solutions or suspensions containmg from about 0 05 to 5% suspending agent m an isotomc medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active mgredient m combmation with the earner, more usually between about 5% and 60% by weight The effective dosage of active mgredient employed may vary dependmg on the particular compound employed, the mode of admimstration and the seventy of the condition being treated However, m general, satisfactory results are obtained when the compounds of the mvention are administered at a daily dosage of from about 0 5 to about 500 mg/kg of animal body weight, preferably given m divided doses two to four times a day, or m a sustained release form For most large mammals, the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg Dosage forms suitable for internal use compπse from about 0 5 to 500 mg of the active compound in intimate admixture with a sohd or liquid pharmaceutically acceptable caπier This dosage regimen may be adjusted to provide the optimal therapeutic response For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation These active compounds may be admmistered orally as well as by intravenous, intramuscular, or subcutaneous routes Sohd earners mclude starch, lactose, dicalcium phosphate, microcrystalhne cellulose, sucrose and kaolm, while liquid earners mclude sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropnate to the nature of the active mgredient and the particular form of admimstration desired Adjuvents customarily employed m the preparation of pharmaceutical compositions may be advantageously mcluded, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are sohd compositions, particularly tablets and hard- filled or hquid-filled capsules Oral administration of the compounds is preferred These active compounds may also be administered parenterally or mtrapentoneally Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared m water suitably mixed with a surfactant such as hydroxypropylcellulose Dispersions can also be prepared m glycerol, liquid, polyethylene glycols and mixtures thereof m oils Under ordinary conditions of storage and use, these preparations contam a preservative to prevent the growth of microorganisms The pharmaceutical forms suitable for injectable use mclude sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions In all cases, the form must be steπle and must be fluid to the extent that easy syrmge ability exits It must be stable under conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi The earner can be a solvent or dispersion medium containmg, for example, water, ethanol (e g , glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil The following examples illustrate preparation of compounds of the mvention EXAMPLE 1 2-(2-Amino-5-bromophenyl)propan-2-ol A solution of 2-ammo-5-bromobenzoιc acid (lOg, 46 mmol) in dry THF (200 mL) was treated at -78 °C under mtrogen with a solution of methylmagnesium bromide in ether (3 0 M, 90 mL, 270 mmol) The reaction mixture was slowly warmed to ambient temperature, kept stirring for 48 hours under nitrogen and then poured mto a cold 0 5 N aqueous hydrochlonde solution (300 mL) The mixture was neutralized with aqueous 1 N sodium hydroxide solution and ethyl acetate (300 mL) was added The organic layer was separated and aqueous layer was extracted with ethyl acetate (3x100 mL) The combined organic layers were washed with brine and dned (MgS0 4 ) After removal of solvent in vacuo, the residue was purified by a silica gel flash chromatography (hexane ethyl acetate/3 2) to give 2-(2-amιno-5- bromophenyl)propan-2-ol as an off-white solid (6g, 57%) mp 62-63 °C, Η-NMR (CDC1 3 ) δ 7 19 (d, 1H, J = 2 3 Hz), 7 12 (dd, 1H, J = 8 4, 2 3 Hz), 6 51 (d, 1H, J = 8 4 Hz), 4 70 (s, 2H), 1 82 (s, 1H), 1 65 (s, 6H) EXAMPLE 2 6-Bromo-4,4-dimethvi-l,4-dihvdro-benzofdlU,31oxazin-2-one To a solution of 2-(2-amιno-5-bromophenyl)propan-2-ol (18g, 78 mmol) m dry THF (150 mL) was added l, -carbonyldiimidazole (15 5g, 94 mmol) under mtrogen The reaction solution was heated at 50 °C overnight The solvent was removed in vacuo and the residue was dissolved in ethyl acetate (100 mL) The solution was washed with IN aqueous hydrochlonde solution (2x40 mL), brine (20 mL). and dned with MgS0 4 After removal of solvent in vacuo, 6-bromo-4,4-dιmethyl-l,4-dιhydro- benzo[d][l,3]-oxazιn-2-one was obtained as a white sohd (20 g, 100%) mp 199-200 °C, Η-NMR (DMSO-de) δ 10 32 (s, 1H, D 2 0 exchangeable), 7 48 (d, 1H, J = 2 1 Hz), 7 43 (dd, 1H, J- 8 5, 2 1 Hz), 6 84 (d, 1H, J - 8 4 Hz), 1 61 (s, 6H) EXAMPLE 3 (1.4-Dihvdro-4,4-dimethyl-2-oxo-2H-3 -benzoxa-an-6-yl)boronic acid To a solution of 6-bromo-4,4-dιmethyl-l,4-dιhydro-benzo[d][l,3]oxazm-2-one (2g, 7 8 mmol) in anhydrous THF (60 mL) was added a solution of «-BuLι m hexane (10 M, 2 4 mL, 24 mmol) at -78 °C under nitrogen After stirred at -78 °C for 30 mmutes, a slurry was obtained and treated with tπisopropyl borate (6 5 mL, 28 mmol) The reaction solution was slowly warmed to ambient temperature and quenched with IN aqueous hydrochloπc acid solution (60 mL) Ethyl acetate (100 mL) was added and orgamc layer was separated, and aqueous layer was extracted with ethyl acetate (3x60 mL) The combmed organic layer was washed with brine and dned with MgS0 4 The solvent was removed in vacuo and the residue was puπfied by a silica gel flash chromatography (ethyl acetate hexane/2 1) to afford (l,4-dιhydro-4,4-dιmethyl- 2-oxo-2H-3,l-benzoxazιn-6-yl)boronιc acid as a white solid (1 4g, 81%) mp 249-250 °C, ! H-NMR (DMSO-ds) δ 10 21 (s, 1H, D 2 O exchangeable), 7 90-7 95 (br s, 2H, D 2 0 exchangeable ), 7 67 (m, 2H), 6 79 (d, 1H, J = 7 8 Hz), 1 61 (s, 6H), MS (ESI) m/z 222([M+H] + , 87%) EXAMPLE 4 6-(3-Chlorophenyl)-4,4-dimethyl-l,4-dihvdrobenzofdl [l,31oxazin-2-one (Procedure A) A mixture of 6-bromo-4,4-dιmethyl-l,4-dιhydro-benzo[d][l,3]oxazm-2-one (1 5g, 5 9 mmol), 3-chlorophenyl boromc acid (1 83g, 11 7 mmol), tetrakιs(tπphenylphosphme)-palladιum (0) (0 35g, 0 3 mmol), and sodium carbonate (2 48g, 23 4 mmol) in a mixture of DME and water (40 mL/10 mL) was degassed to remove the oxygen and then heated at 85 °C under a blanket of mtrogen for 3 hours The reaction mixture was cooled to ambient temperature and quenched with a saturated aqueous ammonium chloride solution (20 mL) Ethyl acetate (50 mL) was added and the organic layer was separated The aqueous layer was extracted with ethyl acetate (3x15 mL) The combined organic layers were washed with brine and dned with MgS0 The solvent was removed in vacuo and the residue was purified by silica gel flash chromatography (hexane ethyl acetate/2 1) to afford 6-(3- chlorophenyl)-4,4-dιmethyl- 1 ,4-dιhydrobenzo [d] [1,3] oxazm-2-one as a yellowish solid (1 4g, 82%) mp 158-159 °C, Η-NMR (DMSO-de) δ 10 31 (s, 1H, D 2 O exchangeable), 7 75 (s, 1H), 7 61 (m, 3H), 7 46 (t, 1H, J- 7 9 Hz), 7 39 (dd, 1H, J = 7 0, 1 1 Hz), 6 96 (d, 1H, J= 8 6 Hz), 1 68 (s, 6H), Anal Calc For Cι 6 H 14 ClNO 2 -0 1 H 2 0 C, 66 37, H, 4 94, N, 4 84 Found C, 66 14, H, 4 61, N, 4 71 EXAMPLE 5 6-(3-Bromo-5-fluorophenyl)-4,4-dimethyl-l,4-dihvdrobenzo[dlfl,31oxa--in-2-one (Procedure B) A mixture of (l,4-dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxazm-6-yl)boromc acid (2 22g, 10 mmol), l,3-dιbromo-5-fluorobenzene (3 05g, 12 mmol), tetrakιs(tπphenylphosphme)palladιum (0) (0 6g, 0 52 mmol), and sodium carbonate (2 2g, 21 mmol) m a mixture of DME and water (70 mL/15 mL) was degassed to remove the oxygen and then heated at 85 °C under a blanket of mtrogen for 3 hours The reaction mixture was cooled to ambient temperature and quenched with a saturated aqueous ammomum chlonde solution (20 mL) Ethyl acetate (100 mL) was added and orgamc layer was separated The aqueous layer was extracted with ethyl acetate (3x30 mL) The combined orgamc layers were washed with brine and dned with MgS0 4 The solvent was removed in vacuo and the residue was puπfied by a sihca gel flash chromatography (hexane ethyl acetate/1 1) to give 6-(3-bromo-5- fluorophenyl)-4,4-dιmethyl-l,4-dιhydrobenzo[d][l,3]oxazm-2-one as a white sohd (1 4g, 40%) mp 182-183 °C, Η-NMR (DMSO-ds) δ 10 36 (s, 1H, D 2 O exchangeable), 7 78 (s, 1H), 7 58-7 65 (m, 3H), 7 49 (dd, 1H, _/ = 8 3, 1 8 Hz), 6 96 (d, 1H, J = 8 5 Hz), 1 69 (s, 6H), 19 F-NMR (DMSO-d 5 ) δ -112 46 (m, IF), MS (CI) m/z 352([M+Hf, 78%), 350([M+H] + , 75%) Anal Calc For C,eHι 3 BrFNO 2 C. 54 88, H, 3 74, N, 4 00 Found C, 54 83, H. 3 82, N, 3 95 EXAMPLE 6 3-(4,4-DimethvI-2-oxo-l,4-dihydro-2H-benzo[dUl,31oxazin-6-yl)-5- fluorobenzonitrile A mixture of 6-(3-bromo-5-fluorophenyl)-4,4-dιmethyl-2H- benz[d][l,3]oxazm-2-one (lg, 2 8 mmol), zmc cyanide (0 2g, 1 7 mmol), and tetrakιs(tnphenylphosphme)-palladιum (0) (0 2g, 0 17 mmol) m dry DMF (20 mL) was degassed to remove oxygen and was then heated at 85 °C under a blanket of mtrogen for 6 5 hours The reaction solution was cooled to room temperature and poured onto a cold saturated aqueous ammomum chloπde solution (100 mL) The white precipitate appeared and was collected on a filter The white sohd was washed with distilled water (3x20 mL) and dissolved m a mixture of ethyl acetate (10 mL) and methanol (10 mL) The solution was apphed on a pad of sihca gel and eluted with a mixture of ethyl acetate and hexane (1 1) After solvent was removed, 3-(4,4- dιmethyl-2-oxo- 1 ,4-dιhydro-2H-benzo [d] [ 1 ,3] oxazm-6-yl)-5-fluoro benzonitnle was obtained as a white solid (0 7g, 84%) mp 253-254 °C, Η-NMR (DMSO-d 6 ) δ 10 4 (s. IH, D 2 0 exchangeable), 8 13 (s, IH), 7 92 (m, IH), 7 82 (m, IH), 7 73 (m, 2H), 6 98 (d, IH, J= 8 2 Hz), 1 68 (s, 6H), 19 F-NMR (DMSO-d 6 ) δ -112 25 (m, IF), MS (El) m/∑ 296(M + , 65%), Anal Calc For C,7H 13 FN 2 θ2 C, 68 91, H, 4 42, N, 9 45 Found C, 68 85, H, 4 58, N, 9 14 EXAMPLE 7 4-(4,4-Dimethyl-2-oxo-l,4-dihydro-2H-benzofdl [l,31oxazin-6-yl)-thiophene-2- carbonitrile The product was prepared, from (l,4-dιhydro-4,4-dιmethyl-2-oxo-2H-3,l- benzoxazιn-6-yl)boronιc acid and 4-bromo-2-thιophenecarbomtπle accordmg to the procedure outhned in Example 5, as a yellowish solid mp 230-231 °C (decomposed), Η-NMR (CDC1 3 ) δ 8 32 (s, IH, D 2 0 exchangeable), 7 83 (d, IH, J= 1 5 Hz), 7 61 (d. IH, J= 1 4 Hz), 7 43 (dd, IH, J= 8 2, 1 9 Hz), 7 29 (d, IH, J= 1 8 Hz). 6 85 (d, 1H, J= 8.2 Hz), 1.78 (s, 6H); MS (El) m/z 283 ([M-H]-, 100%); Anal. Calc. For Ci5H 12 N 2 O 2 S-0.2 H 2 0: C, 62.57, H, 4.34, N, 9.73. Found: C, 62.48, H, 4.31, N, 9.64. EXAMPLE 8 6-(3-ChIorophenyl)-4,4-dimethyl-l < 4-dihvdro-benzo[dlfl.,31oxazin-2-thione A mixture of 6-(3-chlorophenyl)-4,4-dimethyl-l,4-dihydro-benzo[d]- [l,3]oxazin-2-one (0.15g, 0.5 mmol) and Lawesson's reagent (0.24g, 0.6 mmol) in anhydrous o-xylene was heated at reflux under nitrogen for 3 hours. The solvent was removed and the residue was purified by a flash chromatography (sihca gel, hexane:ethyl acetate/6: 1) to afford the title compound as a white sohd (80 mg, 52%): mp 183-184 °C; Η-NMR (DMSO-d 6 ) δ 12.25 (s, IH, D 2 0 exchangeable), 7J8 (t, IH, J= 1.7 Hz), 7.63-7J0 (m, 3H), 7.49 (t, IH, J- 7.8 Hz), 7.42 (d, IH, J= 8.1 Hz), 7.12 (d, 8.8 Hz), 1.72 (s, 6H); MS (El) m/z 303 (-vT, 100%), 305 (M\ 32%); Anal. Calc. For C, 6 Hι 4 ClNOS: C, 63.26, H, 4.64, N, 4.61. Found: C, 63.37, H, 4.62, N, 4.54. EXAMPLE 9 4-(4,4-Dimethyl-2-thioxo-l,4-dihvdro-2H-benzordUl.,31oxazin-6-vI)-thiophene-2- carbonitrile A mixture of 4-(4,4-dimethyl-2-oxo-l,4-dihydro-2H-benzo[d][l,3]oxazin-6- yl)-thiophene-2-carbonitrile (0.23g, 0.8 mmol) and Lawesson's reagent (0.38g, 0.96 mmol) in anhydrous o-xylene was heated to reflux under nitrogen for 3 hours. The solvent was removed in vacuo and the residue was purified by a flash chromatography (sihca gel, hexane: ethyl acetate/3: 1) to afford the title compound as a yellow solid (85 mg, 35%): mp 242-243 °C; Η-NMR (DMSO-de) δ 12.22 (s, IH, D 2 0 exchangeable), 8.50 (d, lH, J= 1.2 Hz), 8.37 (d, 1H, J = 1.0 Hz), 7.71 (m. 2H), 7.09 (d, 1H, J= 8.0 Hz), 1.69 (s, 6H); MS (APCI) m/z 301 ([M+H] + , 100%); Anal. Calc. For C 15 H 12 N 2 OS 2 : C, 59.97, H, 4.03, N, 9.33. Found: C, 59.67, H, 3.85, N, 9.14. EXAMPLE 10 6-Bromo-4,4-dimethyl-l,4-dihydro-benzo.dl, 1 1oxa-rin-2-thione The product was prepared, from 6-bromo-4,4-dimethyl-l,4-dihydro- benzo[d][l,3]oxazin-2-one and Lawesson's reagent using the procedure of Example 9, as a white sohd mp 221-222 5 °C, Η-NMR (CDC1 3 ) δ 9 38 (s, IH, D 2 0 exchangeable). 7 42 (dd, IH, J= 8 5, 2 1 Hz), 7 29 (d, IH, J= 2 0 Hz), 6 76 (d, IH, J = 8 4 Hz), 1 76 (s, 6H), MS (El) m/z 272 ([M+H] + , 94%), 274 ([M+H] + , 100%) EXAMPLE 11 3-(4,4-Dimethyl-2-thioxo-l,4-dihvdro-2H-benzordlH.31oxazin-6-vI)-5- fluorobenzonitrile The product was prepared, from 3-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H- benzo[d][l,3]oxazm-6-yl)-5-fluorobenzonιtπle and Lawesson's reagent usmg the procedure of Example 9, as a yellow sohd 248-249 °C, Η-NMR (DMSO-ds) δ 12 3 (s, IH), 8 15 (bs, IH), 8 02 (d, IH, J= 10 48 Hz), 7 85-7 78 (m, 3H), 7 13 (d, IH, J = 8 92 Hz), 1 71 (s, 6H), MS (APCI) m/z 313([M+H] + , 100%), Anal Calc For C, 7 Hι 3 FN 2 OS C, 65 37, H, 4 19, N, 8 97 Found C, 65 26, H, 4 31, N, 8 61 EXAMPLE 12 3-C4.4-Dimethyl-2-oxo-1.4-dihvdro-2H-benzo[dlH.31oxazin-6-yl)-benzonitriIe A mixture of (l,4-dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxazm-6-yl)boromc acid (2 22g, 10 mmol), 3-bromobenzomtπle (2 18 g, 12 mmol), tetrakιs(tnphenylphosphιne)palladιum (0) (0 6g, 0 52 mmol), and sodium carbonate (2 2g, 21 mmol) in a mixture of DME and water (70 mL/15 mL) was degassed to remove the oxygen and then heated at 85 °C under a blanket of nitrogen for 3 hours The reaction mixture was cooled to ambient temperature and quenched with a saturated aqueous ammomum chlonde solution (20 mL) Ethyl acetate (100 mL) was added and the orgamc layer was separated The aqueous layer was extracted with ethyl acetate (3x30 mL) The combmed orgamc layers were washed with brme and dned with MgS0 4 The solvent was removed in vacuo and the residue was puπfied by a sihca gel flash chromatography (hexane ethyl acetate/1 1) to give 3-(4,4-dιmethyl-2- oxo-l,4-dihydro-2H-benzo[d][l,3]oxazm-6-yl)-benzomtr-le as an off-white sohd (0 7g, 25%) mp 236-237 °C, Η-NMR (DMSO-d 6 ) δ 10 34 (s, IH, D 2 O exchangeable), 8 21 (s, IH), 8 02 (d, IH, J= 8 1 Hz), 7 79 (d, IH, J = 7 7 Hz), 7 60- 7 70 (m, 3H), 6 98 (d, IH, J= 8 2 Hz), 1 71 (s, 6H), Anal Calc For C 17 H 14 N 2 O 2 -0 1 H 2 0 C, 72 89, H, 5 11, N, 10 00 Found C, 72 75, H, 5 05, N, 9 65 EXAMPLE 13 3-(4,4-Dimethyl-2-thioxo-l,4-dihvdro-2H-benzo[dl[l,31oxazin-6-yl)-benzonitrile A mixture of 3-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6- yl)-benzomtπle (1 g, 3 6 mmol) and Lawesson's reagent (1 8 g, 4 3 mmol) m o-xylene (30 mL) was heated at reflux overnight The reaction mixture was cooled to room temperature, poured mto ethyl acetate (50 mL) and washed with 1 N HC1 (2x20 mL) The organic layer was dned over sodium sulfate and concentrated The residue was purified via flash chromatography (sihca gel, 20% ethyl acetate/hexane) to give 3-(4,4- dιmethyl-2-thιoxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6-yl)-benzomtnle (0 21 g, 20%) as a white sohd mp 236-237°C, 'H-NMR (DMSO-d 6 ) δ 12 3 (s, IH), 8 24 (s, IH), 8 05 (d, IH, J= 8 07 Hz), 7 82 (d, IH, J= 7 68 Hz), 7 74-7 64 ( , 3H), 7 14 (d, IH, J= 8 78 Hz), 1 71 (s, 6H), MS (APCI) m/z 295 ([M + H] + , 100%), Anal Calc For C, 7 Hι 4 N 2 OS C, 69 36, H, 4 79, N, 9 52 Found C, 68 35, H, 4 91, N, 9 07 EXAMPLE 14 Potency in the relevant assays The compounds of this mvention were tested in the relevant assay as described below and their potency are m the range of 0 01 nM to 5 μM m the in vitro assays and 0 001 to 300 mg/kg m the in vivo assays The selected examples are hsted m Table 1 below Table 1 Ovulation hPR CV-1 Inhibition Compound R, R 2 R 3 (nM) (mg/kg) 3-chlorophenyl Me Me 0.65 ND* 4-(2-cyanothio- Me Me 0.3 phenyl) 3 -cyano-5-fluoro - Me Me 5.1 ND phenyl 3-cyanophenyl Me Me 0.4 ** * ND, not determined; ** alkaline phosphatase data. (1) T47D cell proliferation assay The objective of this assay is the determination of progestational and antiprogestational potency by using a cell proliferation assay in T47D cells. A compound's effect on DNA synthesis in T47D cells is measured. The materials and methods used in this assay are as follows. a. Growth medium: DMEM:F12 (1: 1) (GIBCO, BRL) supplemented with 10% (v/v) fetal bovine serum (not heat- lnactivated), lOOU/ml pemcilhn, lOOmg/ml streptomycm, and 2 mM GlutaMax (GIBCO, BRL) b Treatment medium Minimum Essential Medium (MEM) (#51200-038GIBCO, BRL) phenol red-free supplemented with 0 5% charcoal stripped fetal bovme serum, lOOU/ml pemcilhn, 200 mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL) c Cell culture Stock T47 D cells are maintained m growth medium. For BrdU incorporation assay, cells are plated m 96- well plates (Falcon, Becton Dickinson Labware) at 10,000 cells/well m growth medium. After overnight mcubation, the medium is changed to treatment medium and cells are cultured for an additional 24 hr before treatment Stock compounds are dissolved in appropriate vehicle (100% ethanol or 50% ethanol/50% DMSO), subsequently diluted m treatment medium and added to the cells Progestin and antiprogestin reference compounds are run m full dose-response curves The final concentration of vehicle is 0 1% In control wells, cells receive vehicle only Antiprogestins are tested m the presence of 0 03 nM tπmegestone, the reference progestm agonist Twenty-four hours after treatment, the medium is discarded and cells are labeled with 10 mM BrdU (Amersham Life Science, Arlington Heights, IL) m treatment medium for 4 hr d Cell Proliferation Assay At the end of BrdU labeling, the medium is removed and BrdU incorporation is measured usmg a cell proliferation ELISA kit (#RPN 250, Amersham Life Science) accordmg to manufacturer's instructions Bπefly, cells are fixed m an ethanol containmg fixative for 30 min, followed by mcubation m a blocking buffer for 30 mm to reduce background Peroxidase-labeled anti-BrdU antibody is added to the wells and incubated for 60 mm The cells are πnsed three times with PBS and mcubated with 3,3'5,5'-tetramethylbenzιdιne (TMB) substrate for 10-20 mm dependmg upon the potency of tested compounds Then 25 μl of 1 M sulfuric acid is added to each well to stop color reaction and optical density is read m a plate reader at 450 nm withm 5 mm e Analysis of Results Square root-transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers. EC 5 o or IC 5 o values are calculated from the retransformed values. JMP software (SAS Institute, Inc.) is used for both one-way analysis of variance and non-linear dose response analyses in both single dose and dose response studies. f. Reference Compounds: Trimegestone and medroxyprogesterone acetate (MPA) are reference progestins and RU486 is the reference antiprogestin. All reference compounds are run in full dose-response curves and the EC 5 o or IC 5 o values are calculated. Table 2. Estimated EC50, standard error (SE), and 95% confidence intervals (CI) for individual studies Compound Exp (nM) SE lower upper Trimegestone 1 0.017 0.003 0.007 0.040 2 0.014 0.001 0.011 0.017 3 0.019 0.001 0.016 0.024 MPA 1 0.019 0.001 0.013 0.027 2 0.017 0.001 0.011 0.024 Table 3. Estimated IC50 . standard error, and 95% confident interval for the antiprogestin, RU486 Compound Exp (nM) SE lower upper RU486 1 0.011 0.001 0.008 0.014 2 0.016 0.001 0.014 0.020 3 0.018 0.001 0.014 0.022 EC 5 o Concentration of a compound that gives half-maximal mcrease in BrdU incorporation with SE, IC50 Concentration of a compound that gives half-maximal decrease m 0 1 trimegestone mduced BrdU incorporation with SE (2) Rat deciduahzation assay The objective of this procedure is used to evaluate the effect of progestms and antiprogest s on rat uterine deciduahzation and compare the relative potencies of vaπous test compounds The mateπals and methods used m this assay are as follows a Methods: Test compounds are dissolved in 100% ethanol and mixed with com oil (vehicle) Stock solutions of the test compounds m oil (Mazda™) are then prepared by heatmg (-80 °C) the mixture to evaporate ethanol Test compounds are subsequently diluted with 100% com oil or 10% ethanol m com oil pπor to the treatment of animals No difference m decidual response was found when these two vehicles were compared b Animals (RACUC protocol #5002) Ovaπectomized mature female Sprague-Dawley rats (~60-day old and 230g) are obtained from Tacomc (Taconic Farms, NY) following surgery Ovaπectomy is performed at least 10 days pnor to treatment to reduce circulating sex steroids Animals are housed under 12 hr light/dark cycle and given standard rat chow and water ad libitum c Treatment Rats are weighed and randomly assigned to groups of 4 or 5 before treatment Test compounds m 0 2 ml vehicle are administered by subcutaneous injection in the nape of the neck or by gavage usmg 0 5 ml The animals are treated once daily for seven days For testmg antiprogestms, animals are given the test compounds and a EC50 dose of progesterone (5 6 mg/kg) duπng the first three days of treatment Following decidual stimulation, animals continue to receive progesterone until necropsy four days later d Dosing Doses are prepared based upon mg/kg mean group body v. eight In all studies, a control group receiving vehicle is mcluded Determination of dose-response curves is carried out usmg doses with half log mcreases (e g 0 1, 0 3, 1 0, 3 0 mg/kg) e Decidual induction Approximately 24 hr after the third injection, deciduahzation is mduced in one of the uterme horns by scratching the ant mesometnal luminal epithelium with a blunt 21 G needle The contralateral hom is not scratched and serves as an unstimulated control Approximately 24 hr following the final treatment, rats are sacrificed by Cθ2 asphyxiation and body weight measured Uteπ are removed and tπmmed of fat Deciduahzed (D-hom) and control (C-hom) uteπne homs are weighed separately f Analysis of Results The mcrease m weight of the deciduahzed uterme hom is calculated by D-horn/C-horn and logaπthmic transformation is used to maximize normality and homogeneity of vanance The Huber M-estimator is used to down weight the outlymg transformed observations for both dose-response curve fittmg and one-way analysis of vanance JMP software (SAS Institute, Inc ) is used for both oneway ANOVA and non-lmear dose-response analyses g Reference Compounds All progestm reference compounds were run m full dose- response curves and the EC 5 o for uterme wet weight were calculated Table 4. Estimated ECso, standard error (SE), and 95% confidence intervals for individual studies Compound Exp (mg/kg. s c ) SE lower upper Progesterone 1 5 50 0 77 4 21 7 20 2 6 21 1 12 4 41 8 76 3-Ketodesogestrel 1 0 11 0 02 0 07 0 16 2 0 10 0 05 0 11 0 25 3 0 06 0 03 0 03 0 14 gestrel 1 0 08 0 03 0 04 0 16 2 0 12 0 02 0 09 0 17 3 0 09 0 02 0 06 0 13 4 0 09 0 02 0 06 0 14 1 0 42 0 03 0 29 0 60 2 0 39 0 05 0 22 0 67 3 0 39 0 04 0 25 0 61 Table 5. Estimated average EC 5 o, standard error, and 95% confidence intervals for dose-response curves of 3 reference compounds EC50 95% CI Compound (mg/kg. s c ) SE lower upper Progesterone 5 62 0 62 4 55 7 00 3-Ketodesogestrel 0 10 0 02 0 07 0 14 Levonorgestrel 0 10 0 01 0 08 0 12 Table 6. Estimated IC50, standard error, and 95% confident interval for the antiprogestin, RU 486 Compound Exp (mg/kg. p o ) SE lower upper RU 486 1 0 21 0 07 0 05 0 96 2 0 14 0 02 0 08 0 27 Concentration Compound concentration in assay(default-mg/kg body weight) Route of administration Route the compound is admmistered to the animals Body weight Mean total animal body weight (default-kg) D-hom Wet weight of deciduahzed uterme hom (default-mg) C-hom Wet weight of control uterine hom (default-mg) Decidual response [(D-C)/C]xl00% Progestational activity Compounds that mduce deciduahzation significantly (p<0 05) compared to vehicle control are considered active Antiprogestational activity Compounds that decrease EC 5 o progesterone mduced deciduahzation significantly (p<0 05) EC 50 for uterme weight Concentration of compound that gives half-maximal increase m decidual response (default-mg/kg) IC50 for uterme weight Concentration of compound that gives half-maximal decrease m EC 50 progesterone mduced decidual response (default-mg/kg) (3) PRE-luciferase assay in CV-1 cells The object of this assay is to determine a compound's progestational or antiprogestational potency based on its effect on PRE-luciferase reporter activity m CV-1 cells co-transfected with human PR and PRE-luciferase plasmids The materials methods used m the assay are as follows a Medium The growth medium was as follows DMEM (BioWhittaker) containmg 10% (v/v) fetal bovme serum (heat mactivated), 0 1 mM MEM non-essential ammo acids, lOOU/ml pemcilhn, lOOmg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL) The experimental medium was as follows DMEM (BioWhittaker), phenol red-free, containmg 10% (v/v) charcoal-stripped fetal bovme serum (heat-mactivated), 0 1 mM MEM non-essential ammo acids, lOOU/ml pemcilhn, 1 OOmg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL) b Cell culture, transfection. treatment, and luciferase assay Stock CV-1 cells are maintained m growth medium. Co- transfection is done usmg 1 2x10 7 cells, 5 mg pLEM plasmid with hPR-B inserted at Sphl and BamHl sites, 10 mg pGL3 plasmid with two PREs upstream of the luciferase sequence, and 50 mg somcated calf thymus DNA as carrier DNA m 250 ml Electroporation is earned out at 260 V and 1,000 mF m a Biorad Gene Pulser II After electroporation, cells are resuspended m growth medium and plated in 96-well plate at 40,000 cells/well in 200 μl Folio wing overnight mcubation, the medium is changed to experimental medium Cells are then treated with reference or test compounds m experimental medium Compounds are tested for antiprogestational activity in the presence of 3 nM progesterone Twenty-four hr after treatment, the medium is discarded, cells are washed three times with D-PBS (GIBCO, BRL) Fifty μl of cell lysis buffer (Promega, Madison, WI) is added to each well and the plates are shaken for 15 mm m a Titer Plate Shaker (Lab Lme Instrument, Inc ) Luciferase activity is measured usmg luciferase reagents from Promega c Analysis of Results Each treatment consists of at least 4 replicates Log transformed data are used for analysis of vanance and nonlinear dose response curve fittmg for both agomst and antagonist modes Huber weightmg is used to downweight the effects of outhers EC 5 o or IC 5 o values are calculated from the retransformed values JMP software (S AS Institute, Inc ) is used for both one-way analysis of vanance and non-hnear response analyses d Reference Compounds Progesterone and tπmegestone are reference progestins and RU486 is the reference antiprogestin All reference compounds are run m full dose- response curves and the EC50 or IC50 values are calculated Table 8. Estimated EC50 . standard error (SE), and 95% confidence intervals (CI) for reference progestins from three individual studies EC50 95% CI Compound Exp (nM) SE lower upper Progesterone 1 0 616 0 026 0 509 0 746 2 0 402 0 019 0 323 0 501 3 0 486 0 028 0 371 0 637 Tπmegestone 1 0 0075 0 0002 0 0066 0 0085 2 0 0081 0 0003 0 0070 0 0094 3 0.0067 0.0003 0.0055 0.0082 Table 9. Estimated IC 5 o, standard error (SE), and 95% confident interval (CI) for the antiprogestin, RU486 from three individual studies IC 50 95% CI Compound Exp. (nM) SE lower upper RU486 1 0.028 0.002 0.019 0.042 2 0.037 0.002 0.029 0.048 3 0.019 0.001 0.013 0.027 Progestational activity: Compounds that increase PRE-luciferase activity significantly (p<0.05) compared to vehicle control are considered active. Antiprogestational activity: Compounds that decrease 3 nM progesterone induced PRE-luciferase activity significantly (p<0.05). EC 5 o: Concentration of a compound that gives half-maximal increase PRE-luciferase activity (default-nM) with SE. IC 50 : Concentration of a compound that gives half-maximal decrease in 3 nM progesterone induced PRE-luciferase activity (default-nM) with SE. EXAMPLE 15 WAY-166494: 6-(3-fluorophenyl)-4-methyl-l,4-dihvdro-2H-3,l-benzoxazine-2- thione 4-Amino-3'-fluoro[l,r-biphenyl]-3-carbonitrile was prepared from 3- fluorophenyl boronic acid and 2-amino-5-bromobenzonitrile according to the procedure of Example 4. A solution of 4-amino-3'-fluoro[l,r-biphenyl]-3-carbonitrile (6.65g, 31.3 mmol) in anhydrous THF (100 mL) was treated drop wise at room temperature under nitrogen with methylmagnesium bromide (3.0 M in ether, 21 mL, 63 mmol). The reaction mixture was then heated at gentle reflux for 1.5 hours, cooled to room temperature, and treated with 3N aqueous hydrogen chloride solution (30 mL). The resulted mixture was heated at reflux for 3 hours, cooled to ambient temperature, and adjusted to a pH of 5-6 by the addition of a saturated aqueous sodium carbonate solution. Ethyl acetate (100 mL) was added, the organic layer was separated and the aqueous layer was extracted with ethyl acetate (3x50 mL) The combmed orgamc layers were dried (MgS0 4 ) and evaporated The residue was purified by a silica gel chromatography (hexane ethyl acetate/3 1) to afford l-(4- ammo-3'-fluoro[l,r-bιphenyl]-3-yl)ethanone (3 lg, 43%) mp 156-157 °C A solution of l-(4-ammo-3'-fluoro[l,r-bιphenyl]-3-yl)ethanone (3g, 13 mmol) m anhydrous methanol (60 mL) was then treated at room temperature under mtrogen with sodium borohydπde m a portion wise manner After addition, the reaction mixture was stirred for 4 hours, treated with a saturated solution of aqueous ammonium sulfate (50 mL) and ethyl acetate (100 mL) The orgamc layer was separated, dned (MgS0 4 ), and evaporated in vacuo The residue was purified on a sihca gel chromatography (hexane ethyl acetate/3 1) to yield l-(4-ammo-3'-fluoro[l,l'- bιphenyl]-3-yl)ethanol as a white sohd (2g, 67%) mp 136-137 °C A mixture of the above alcohol (0 2g, 0 87 mmol) and tnphosgene m anhydrous THF (20 mL) was stiπed at room temperature under mtrogen After 15 minutes, the mixture was treated with a saturated aqueous sodium bicarbonate solution (30 mL) and ethyl acetate (40 mL) The organic layer was separated, dried (MgSO 4 ), and evaporated to give 6-(3-fluorophenyl)-4-methyl-l,4-dιhydro-2H-3,l-benzoxazιn- 2-one as a white sohd (0 18g, 81%) mp 160-161 °C, *H-NMR (DMSO- 6 ) δ 10 31 (s, IH), 7 62 (dd, IH, J= 8 2, 1 9 Hz), 7 57 (s, IH), 7 44-7 53 ( , 3H), 7 13-7 20 (m IH), 6 97 (d, lH, J= 8 2 Hz), 5 57 (q, lH, J= 6 6 Hz), 1 63 (d, 3H, J= 6 6 Hz) MS (ESI) m/z 256 [M - H] A solution of 6-(3-fluorophenyl)-4-methyl-l,4-dιhydro-2H-3, l-benzoxazιn-2- one (0 15g, 0 58 mmol) m toluene was treated with Lawesson's reagent accordmg to the procedure m example 9 to yield 6-(3-fluorophenyl)-4-methyl-l,4-dιhydro-2H-3,l- benzoxazιn-2-thιone (0 08g, 50%) as an off-white sohd (0 08g, 50%) mp 173-174 °C, 'H-NMR (DMSO-- ) δ 12 27 (s, IH), 7 70 (dd, IH, J= 8 2. 2 0 Hz), 7 62 (s, IH), 7 46-7 56 (m, 3H), 7 15-7 22 (m, IH), 7 11 (d, IH, J= 8 3 Hz), 5 64 (q, IH, J= 6 6 Hz), 1 67 (d, 3H, J= 6 6 Hz), MS (ESI) m/z 272 [M - H] EXAMPLE 16 5-(4,4-Dimethyl-2-thioxo-l,4-dihydro-2H-3,l-benzoxazin-6-yl)-4- methylthiophene-2-carbonitrile 5-(4, 4-Dιmethyl-2-oxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6-yl)-4-methyl- thιophene-2-carbomtnle was prepared, accordmg to the procedure m Example 5 usmg (l,4-d-hydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxazm-6-yl)boronιc acid and 5-bromo- 4-methyl-2-thιophenecarbomtnle, as an off-white sohd mp 195-200 °C, Η-NMR (DMSO-ds) δ 10 2 (s, IH), 8 32 (s, IH), 7 41-7 44 (m, 2H), 7 01 (d, IH, J= 8 8 Hz), 2 28 (S, 3H), 1 64 (S, 6H), MS (APCI) m/z 299 [M+H] + , Anal Calc For C 16 H 14 N 2 O 2 S, C, 64 41, H, 4 75, N, 8 89 Found C, 64 64, H, 4 62, N, 9 39 To a solution of 5-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-3,l-benzoxazιn-6-yl)- 4-methylthιophene-2-carbonιtnle (5g, 16 7 mmol) m anhydrous toluene was added, at room temperature under a blanket of mtrogen, Lawesson's reagent (6g, 14 8 mmol) The reaction mixture was heated at reflux for 2 hrs, allowed to cool to room temperature, and solvent was removed in vacuo The residue was purified by a silica gel column chromatography (THF hexane/1 3) to yield the title compound as a yellowish solid (2 4g, 46%) mp 211-212 °C, Η-NMR (DMSO-de) δ 12 3 (s, IH), 7 88 (s, IH), 7 46-7 52 (m, 2H), 7 16 (d, IH, J= 8 3 Hz), 2 30 (S, 3H), 1 68 (S, 6H), MS (ESI) m/z 313 [M-H] , Anal Calc For C 16 H 14 N 2 OS 2 , C, 61 12, H, 4 49, N, 8 91 Found C, 60 91, H, 4 48, N, 8 66 EXAMPLE 17 tert-Butyl 2-cyano-5-(4,4-dimethyl-2-thioxo-l,4-dihvdro-2H-3,l-benzoxazin-6-yl)- lH-pyrrole-1-carboxylate A solution of 6-bromo-4,4-dιmethyl-l,4-dιhydro-benzo[d][l,3]oxazm-2-one (5 0 g, 20 mmol) and tetrakιs(tnphenylphosphme)palladιum(0) (580 mg, 0 5 mmol) in toluene (200 mL) was stirred under a flow of nitrogen for 25 min To the solution was added sequentially l-tert-butoxycarbonylpynole-2-boromc acid (8 24 g, 39 mmol) in absolute ethanol (50 mL) and potassium carbonate (5 39 g, 39 mmol) in water (50 mL) The mixture was heated to 80 °C for 16 h and allowed to cool The reaction mixture was poured mto an aqueous saturated sodium bicarbonate solution (200 mL) and extracted with ethyl acetate (3 x 200 mL) The orgamc layers were combmed, washed with water (200 mL) and brme (100 mL) and dried over magnesium sulfate The solution was filtered, concentrated in vacuo, and the residue was purified by flash column chromatography on sihca gel (30% ethyl acetate/hexane) to give 2-(4,4- dimethyl-2-oxo-l,4-dihydro-2H-benzo [d] [1,3] oxazm-6-yl)-pyrrole-l-carboxyhc acid tert-butyl ester (4 0 g, 58%) as a tan sohd, mp 172-173 °C To a solution of 2-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-benzo [d] [1,3] oxazin- 6-yl)-pyrrole-l-carboxyhc acid tert-butyl ester (2 0 g, 5 8 mmol) in THF (anhydrous, 50 mL) at -78 °C was added chlorosulfonyl isocyanate (0 66 mL, 6 7 mmol) After 90 mm, DMF (9 mL, 116 mmol) was added and the reaction was allowed to warm to room temperature The reaction mixture was poured mto water (50 mL) and the product was extracted with ethyl acetate (2 x 50 mL) The organic layers were combmed, washed with brme (50 mL), dned over magnesium sulfate, filtered and concentrated in vacuo Puπfication via flash column chromatography on sihca gel (30%) ethyl acetate/hexane) gave 2-(4,4-dιmethyl-2-oxo-l ,4-dιhydro-2H-benzo [d] [1,3] oxazm-6-yl)-5-cyano-pyπole- 1-carboxy he acid tert-butyl ester (1 1 g, 52%) as a white powder, mp 165-167 °C, Η NMR (DMSO-<- ) δ 1 36 (s, 9H), 1 61 (s, 6 H), 6 44 (d, 1 H, J= 3 7 Hz), 6 92 (d, 1 H, J= 8 2 Hz), 7 27-7 32 (m, 2 H), 7 36 ('d\ 1 H, J= 1 5 Hz), 10 36 (s, 1 H), MS (El) m/z 367 [M] + To 2-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-benzo [d] [1,3] oxazιn-6-yl)-5- cyano-pyrrole-1-carboxyhc acid tert-butyl ester (1 3 g, 35 mmol, 1 eq) m toluene (130 mL) was added Lawesson's reagent (1 58 g, 3 9 mmol, 1 1 eq) and the reaction mixture was heated to 80 °C for 2 h The solvent was removed in vacuo and the residue was dissolved m acetone/dichloromethane and adsorbed onto silica gel Purification by flash column chromatography (10% ethyl acetate/hexane) gave the product (0 51 g, 38%) as yellow ciystals Η NMR (DMSO-de) δl 35 (s, 9 H), 1 64 (s, 6 H), 6 47 (d, 1 H, J= 3 6 Hz), 7 07 (d, 1 H, J= 8 1 Hz), 7 32 (d, 1 H, J= 3 6 Hz), 7 37 (dd, 1 H, J= 1 8, 8 1 Hz), 7 43 (d, 1 H, J= 1 8 Hz), 12 28 (s, 1 H), MS (ESI) [M-H] = 382, Anal Calcd For C 20 H 21 N 3 O 3 S C, 62 64, H, 5 52, N, 10 96 Found C, 62 53, H, 5 6, N, 10 87 EXAMPLE 18 5-(4,4-D-methyl-2-thioxo-l,4-dihvdro-2H-3, l-benzoxazin-6-yl)-lH-pyrrole-2- carbonitrile To a solution of tert-butyl 2-cyano-5-(4,4-dιmethyl-2-thιoxo-l,4-dιhydro-2H- 3.1-benzoxazm-6-yl)-lH-pyrrole-l-carboxylate (0 5 g, 1 3 mmol, 1 eq) m THF (5 mL) was added NaOEt (0 27 g, 3 9 mmol, 3 eq) m EtOH (5 mL) and the reaction was heated to 80°C for 2 h The solvents were removed in vacuo and the residue partitioned between ethyl acetate (100 mL) and water (100 mL) The layers were separated and the aqueous layer was extracted with ethyl acetate (100 mL) The organic layers were combmed, washed with brme (50 mL), dned over magnesium sulfate, filtered and concentrated in vacuo Puπfication by flash column chromatography (10% ethyl acetate/hexane) gave the title compound (0 27g, 73%) as a brown powder, mp 261-262 °C Η NMR (DMSO- 6 ) δ 1 68 (s, 6 H), 6 72 - 6 73 (m, 1 H), 6 99 - 7 01 (m, 1 H), 7 06 (d, 1 H, J= 7 9 Hz), 7 66 - 7 70 (m, 2 H), 12 26 (s, 1 H), 12 62 (s, 1 H), MS (ESI) [M-H] = 282, Anal Calcd For C. 5 H 13 N 3 OS C, 63 58, H, 4 62, N, 14 83 Found C, 63 25, H, 4 78, N, 15 11 EXAMPLE 19 [6-(4,4-dimethyl-2-thioxo-l,4-dihydro-2H-3,l-benzoxa-rin-6-yl)pyridin-2- yll acetonitrile [6-(4,4-dιmethyl-2-oxo- 1 ,4-dιhydro-2H-3 , 1 -benzoxazιn-6-yl)pyndιn-2- }l]acetonιtnle was prepared, accordmg to the procedure of Example 5 usmg (1,4- dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxazm-6-yl)boromc acid and (6-bromo-2- pyndyl)acetonιtnle (J Org Chem 1988, 53, 786-790), as an off-white sohd mp 210- 212 5 °C, ] H NMR (DMSO-. ) δl 68 (s, 6 H), 4 27 (s, 2 H), 7 00 (d, 1 H, J = 8 3 Hz), 7 34 (d, 1 H, J= 7 1 Hz), 7 89 - 7 96 (m, 2 H), 8 00 - 8 05 (m, 2 H), 10 42 (s, 1 H), MS (ESI) [M-H] " = 292, Anal Calcd For Cι 7 H 15 N 3 0 2 C, 69 61, H, 5 15, N, 14 33 Found C, 68 49, H, 5 19, N, 13 74 To [6-(4,4-dιmethyl-2-oxo- 1 ,4-dιhydro-2H-3, 1 -benzoxazin-6-yl)pyndin-2- (80 mg, 0 27 mmol, 1 eq) ιn/. -xylene (10 mL) was added Lawesson's reagent (55 mg, 0 14 mmol, 0 5 eq) and the reaction was heated to reflux for 2 hours The reaction was cooled to room temperature and adsorbed onto sihca gel Purification by flash column chromatography (50% ethyl acetate/hexane) on silica gel gave the title compound (40 mg, 48%) as an off-white solid mp 215-217 °C, ] H NMR (Je-DMSO, 300 MHz) δ 1 71 (s, 6 H), 4 28 (s, 2 H), 7 15 (d, 1 H, J= 8 3 Hz), 7 36 (d, 1 H, J= 7 3 Hz), 7 89 - 7 99 (m, 2 H), 8 04 - 8 11 (m, 2 H), 12 32 (s, 1 H), MS (ESI) [M-H] = 308, Anal calcd for C 17 H 15 N 3 OS C, 66 00, H, 4 89, N, 13 58 Found C, 64 43, H, 4 65, N, 12 95 EXAMPLE 20 5-(4.4-Dimethyl-2-thioxo-l,4-dihydro-2H-3,l-benzoxazin-6-yl-l-methyl-lH- pyrrole-2-carbonitrile 2-(4,4-Dιmethyl-2-oxo-l,4-dιhydro-2H-benzo [d] [1,3] oxazιn-6-yl)-5-cyano- pyπole-1-carboxyhc acid tert-butyl ester (1 g, 2 7 mmol) was placed m a 25 mL round bottomed flask stoppered with a rubber septum and equipped with mtrogen inlet and a needle to allow gaseous outflow A vigorous flow of nitrogen was maintained as the flask was placed m an oil bath and heated to 160 °C After 20 mm at this temperature, the flask was removed from the oil bath and allowed to cool The yellow residue was washed mto a larger flask with dichloromethane/ethyl acetate and adsorbed onto a small amount of silica gel Purification by flash column chromatography on sihca gel (40% ethyl acetate/hexane) gave of 5-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-3,l- benzoxazm-6-yl)-lH-pyπole-2-carbomtπle (340 mg, 47%) as a yellow powder mp 241-242 °C, Η NMR -DMSO, 300 MHz) δ 1 65 (s, 6 H), 6 67 (d, 1 H, J= 3 9 Hz). 6 91 (d, 1 H, J= 8 3 Hz), 6 98 (d, 1 H, J= 3 9 Hz), 7 61 (dd, 1 H, J= 1 8, 8 3 Hz), 7 65 ('d\ 1 H, J= 1 6 Hz), 10 32 (s, 1 H), 12 54 (bs, 1 H), MS (El) m/z 267 M + , Anal Calcd For C 15 H 13 N 3 0 2 C, 67 41, H, 4 90, N, 15 72 Found C, 67 19, H, 4 96, N, 15 35 To a solution of 5-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-3,l-benzoxazm-6-yl)- lH-pyιτole-2-carbomtπle (1 eq, 71 mg, 0 27 mmol) in dimethylformamide (0 5 mL) was added potassium carbonate (5 eq, 0 18 g, 0 1 35 mmol) After 10 mm, lodomethane (3 eq, 05 mL, 0 81 mmol) was added and the suspension was stirred for 2 hours, poured into water (5 mL) and the product was extracted with ethyl acetate (3 x 5 mL) The layers were then separated, the aqueous layer extracted with ethyl acetate (3 x 10 mL) and the combmed organic layer was washed with brme, dned over MgS0 4 and punfied by flash column chromatography on silica gel elutmg with 30% ethyl acetate/hexane to give 5-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-3,l-benzoxazιn-6- yl)-l -methyl- lH-pyrrole-2-carbonιtπle (30 mg, 41%) as a white sohd MS (ES) m/z 280 (M-H) , Anal Calcd For C 16 H 15 N 3 0 2 C, 68 3, H, 5 37, N, 14 9 Found, C, 68 4, H. 5 51. N, 14 6 To a solution of 5-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-3,l-benzoxazm-6-yl)- 1 -methyl- lH-pyrrole-2-carbomtπle (6 0 g, 22 mmol, 1 eq) m toluene (600 mL) was added Lawesson's reagent (5 9 g, 15 mmol, 0 65 eq) and the reaction was heated to 80 °C for 2 hours The reaction was cooled to room temperature, poured mto water (200 mL) and extracted with ethyl acetate (2 x 200 mL) The organic layers were combmed, washed with brme (50 mL), dned over magnesium sulfate, filtered and concentrated in vacuo Puπfication by flash column chromatography (5-10% ethyl acetate/hexane) gave the title compound (2 0 g, 31 %) as a slightly yellow solid mp 225-228 °C l H NMR -DMSO, 300 MHz) δl 67 (s, 6 H), 3 72 (s, 3 H), 6 37 (dd, 1 H, J= 0 8, 4 1 Hz), 7 04 (dd, 1 H, J= 0 8, 4 1 Hz), 7 13 (m, 1 H), 7 47 (m, 2 H), 12 30 (s, 1 H), MS (ESI) [M-H] = 296, Anal calcd for C 16 H 15 N 3 OS C, 64 62, H, 5 08, N, 14 13 Found C, 64 7, H, 5 12, N, 14 17 EXAMPLE 21 5-(4,4-dimethyl-2-thioxo-l,4-dihvdro-2H-3,l-benzoxazin-6-yl)-lH-pyrrole-2- carbothiamide To 4,4-dιmethyl-6-(5-cyano-lH-pyrrol-2-yl)-l,4-dιhydobenzo [d][l,3]oxazm- 2-one (6 0 g, 22 5 mmol) m p-xylβne (100 mL) was added Lawesson's reagent (5 9 g, 14 6 mmol, 0 65 eq) and the reaction was heated to reflux for 3 hours The reaction was cooled to room temperature, concentrated in vacuo, and adsorbed onto silica gel Puπfication by flash column chromatography (30% ethyl acetate/hexane) on sihca gel gave the title compound (1 2 g, 17%) as a yellow powder Η NMR (DMSO-de) D l 69 (s, 6 H), 6 65 (dd, 1 H, J = 2 2, 3 8 Hz), 6 98 (dd, 1 H, J = 2 2, 3 8 Hz), 7 03 (d, 1 H, J= 8 2 Hz), 7 69 (dd, 1 H, J= 1 6, 8 2 Hz), 7 81 (d, 1 H, J= 1 6 Hz), 8 92 (s, 1 H), 9 09 (s, IH), 11 19 (s, 1 H), 12 22 (s, 1 H), MS (ESI) [M+H] + = 318, [M-H] = 316, Anal calcd for C, 5 H, 5 N 3 OS 2 C, 56 76, H, 4 76, N, 13 24 Found C, 56 78, H, 4 87, N, 12 54 EXAMPLE 22 5-(4,4-Dimethyl-2-thioxo-l,4-dihvdro-2H-benzo.dl .1,3 1 oxazin-6-yl) thiophene- 3-carbonitrile 5-(4,4-Dιmethyl-2-oxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6-yl)-thιophene- 3-carbomtnle was prepared, accordmg to the procedure m Example 5 usmg (1,4- dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxιn-6-yl)boronιc acid and 2-bromo-4- thiophenecarbomtπle, as an off-white sohd mp 255-260 °C, Η-NMR (DMSO-d 6 ) δ 10 36 (s, IH), 8 48(d, IH, J= 1 1 Hz),7 88-7 87 (d, 1H J= 1 3 Hz), 7 63 (d, 1H J = 1 9 Hz),7 56-7 54 (dd, IH, J = 8 0, 2 0 Hz), 6 93 (d, IH, J = 8 1 Hz), 1 64 (s, 6H), MS(-ESI) m/z 283 (M-H) The title compound was prepared in a manner similar to Example 16 usmg 5- (4,4-dιmethyl -2-oxo- l,4-dιhydro-2H-benzo [d] [1,3] oxazιn-6-yl) thιophene-3- carbonitnle and Lawesson's reagent The product was obtained m the form of yellow crystals mp 258-259 °C ! H NMR (DMSO-d 6 ) δ 12 3 (s,l H ),8 54 (d, IH, J= 0 9 Hz) ,7 96 (s, IH), 7 69-7 62 (m, 2H), 7 11-7 08 (d, 1 H , J= 8 3 Hz), 1 69 (s, 6H), MS (ESI) m/z 299 [M-H] , Anal Calcd For C ]5 H 12 N 2 OS 2 Vi H 2 0 C, 58 0, H, 4 24, N, 9 05 Found C, 58 33, H, 3 85, N, 8 39 EXAMPLE 23 5-( 4,4-dimethyl-2-thioxo-l,4-dihvdro-2H-3,l-benzoxazin-6-yl )-l-ethyl-lH- pyrrole-2-carbonitrile To a solution of 5-( 4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-3,l-benzoxazιn-6-y-)- lH-pyn-ole-2-carbomtπle (1 3 g, 5 mmol ) m dimethylformamide ( 25 ml) was added potassium carbonate ( 1 g, 7 5 mmol ), and lodomethane ( 0 4 ml, 5 1 mmol ), and the mixture was stiπed at room temperature for 3 hours The mixture was triturated with ethyl acetate/water, and the ethyl acetate layer was separated, dried over magnesium sulfate, and concentrated in vacuo The residue was recrystalhzed from ethyl acetate/hexane to afford 5-( 4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-3,l-benzoxazm-6-yl)- 1 -ethyl- lH-pyrrole-2-carbomtπle (0 4 g, 27% ) mp 200-202 °C, ] H-NMR ( DMSO- de ) δ 1 25 (t, J = 7 2 Hz, 3H), 1 64 (s, 6H), 4 07 (q, J= 7 2 Hz, 2H), 6 29 (d, J= 4 1, Hz, IH), 7 0 (d, J= 8 Hz, IH), 7 05 (d, J= 4 1 Hz, IH), 7 34 (m, 2H), 10 42 (s, IH), MS (ESI) m/z 2 94 (M-H) The title compound was prepared accordmg to the procedure for Example 16 from 5-( 4,4-dιmethyl -2-oxo- 1 ,4-dιhydro-2H-3 , 1 -benzoxazιn-6-yl)- 1 -ethyl- 1 H- and Lawesson's reagent The product was obtamed m the form of white needles mp 212-213 °C, ! H-NMR (DMSO-d 6 ) δ 1 25 (t, 3H, J = 7 Hz), 1 68 (s. 6H), 4 07 (q, J= 7 Hz, 2H), 6 32 (d, J= 3 9 Hz, IH), 7 07 (d, J = 3 9 Hz, IH), 7 15 (d, J= 9 Hz, IH), 7 42 (m, 2H), 12 33 (s, IH), MS (ESI) m/z 310 ( M-H ) " EXAMPLE 23 4-, l,2-Dihvdro-2-thioxospiro,4H-3,l-benzoxazin-4,l-cvclohexan]-6-yl)-2- thiophenecarb onitrile l-(2-Amιno-5-bromo-phenyl) cyclohexanol was prepared, accordmg to the procedure of Example 1 usmg 2-ammo-5-bromobenzoιc acid and the Gngnard reagent prepared from 1,5-dibromopentane, as a clear oil Η-NMR (DMSO-de) δ 7 07 (d, IH. J= 2 3 Hz), 7 03 (dd, IH, J= 8 4, 2 4 Hz), 6 55 (d, IH, J= 8 6 Hz), 5 49 (s, 2H, D 2 0 exchangeable), 5 00 (s, IH, D 2 0 exchangeable), 2 01 (d, 2H, J= 1 8 Hz), 1 66- 1 77 (m, 2H), 1 44-1 61 (m, 4H), 1 16-1 34 (m, 2H), MS (ESI) m/z 270/272 ([M+H] + , 98%/100%) 6-Bromo-spιro[4H-3, l-benzoxazme-4, l'-cyclohexane-2-(lH)-one] was prepared from l-(2-ammo-5-bromo-phenyl) cyclohexanol and carbonyl dnmidazole accordmg to the procedure of Example 2 The product was obtained as an off- white solid mp 208-210 °C, 'H-NMR (DMSO-de) δ 10 26 (s, IH), 7 45 (d, IH, J= 2 2 Hz). 7 39 (dd, 1H, J= 8 2, 2 2 Hz), 6 81 (d, 1H, J = 8 3 Hz), 1 90-1 97 (m, 2H), 1 80- 1 85 (m, 5H), 1 25-1 35 (m. IH), MS (APCI) m/z 296 ([M+H] + , 68%) Spιro-(4, 1 '-cyclohexane- 1, 4-dιhydro-2-oxo-2H-3, 1 -benzoxazm-6-yl) boromc acid, prepared accordmg to the procedure of Example 4 usmg 6-bromo-spιro[4H-3, 1- benzoxazιne-4, l'-cyclohexane-2-(lH)-one, as an off-white sohd mp 223-225 °C Η-NMR (DMSO-de) δ 10 17 (s, IH, D 2 O exchangeable), 7 92 (s, 2H, D 2 0 exchangeable), 7 67 (S, IH), 7 63 (dd, IH, J= 8 0, 1 1 Hz), 6 81 (d, IH, J= 7 9 Hz), 1 96(s, IH), 1 93 (s, IH), 1 57-1 88 (m, 7H), 1 24-1 34 (m, IH), MS (ESI) m/z 262 (M+H) + 4-(l, 2-Dιhydro-2-oxospιro[4H-3,l-benzoxazme-4,l-cyclohexan]-6-yl)-2- thiophenecarbonitnle was prepared, accordmg to the procedure of Example 5 from spιro-(4, 1 '-cyclohexane- 1 ,4-dιhydro-2-oxo-2H-3, 1 -benzoxazιn-6-yl) boromc acid and 3-bromo-5-cyanothιophene, as white crystals mp 230-232 °C, IR (KBr) 2200 cm 1H- NMR (DMSO-de) δ 10 29 (s, IH), 8 49 (s, IH), 8 33 (s, IH), 7 69-7 63 (m, 2H), 6 93- 6 91 (d, IH, J= 8 2 Hz), 1 99-1 87 (m, 4H), 1 73-1 64 (m, 5H), 1 38-1 31 (m, IH), MS(+)APCI m/z 325 (M+H) + , Anal Calc For CsH^N.O.Sl HzO C, 65 73, H, 5 06, N, 8 52 Found C, 65 55, H, 5 06, N, 8 22 The title compound was prepared, accordmg to the procedure of Example 16 usmg 4-(l,2-dιhydro-2-oxospιro[4H-3, l-benzoxazιne-4, l-cyclohexan]-6-yl)-2- thiophenecarbonitπle, as a yellow sohd mp 225-227°C, ] H-NMR (CDC1 3 ) δ 8 98 (s, IH), 7 83 (d, IH, J= 1 47 Hz), 7 63 (d, IH, J= 1 47 Hz), 7 46 (dd, IH, J= 8 2, 1 91 Hz), 7 32 (m, IH), 6 86 (d, IH, J= 8 19 Hz), 2 28-2 29 (m, 2H), 2 06-2 01 (m, 2H), 1 83-1 70 (m, 5H), 1 37-1 3 (m, IH), MS (ES) m/z 339 ([M-H] ) EXAMPLE 25 5-(4,4-Dimethyl-2-thioxo-l,4-dihvdro-2H-3,l-benzoxaz-6-yl)-2-fluorobenzonitrile 3-(4,4-Dιmethyl-2-oxo- 1 ,4-dιhydro-2H-benzo [d] [ 1 ,3] oxazιn-6-yl)-4-fluoro- benzomtπle was prepared, from (l, 4-dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxm-6- yl)boromc acid and 5-bromo-2-fluorobenzonιtπle accordmg to the procedure of Example 5, as a white solid mp 229-230°C, 'H-NMR (DMSO-de) δ 10 4 (s, IH), 8 15 (dd, IH, J = 7 39, 2 12 Hz), 7 95-7 89 (m, IH), 7 59-7 48 (m, 3H), 6 99 (d, IH, J= 8 1 Hz), 1 7 (s, 6H), MS (APCI) m/z 297 ([M + H] + , 100%), Anal Calc For C 17 H, 3 FN 2 0 2 C, 68 91, H, 4 42, N, 9 45 Found C, 68 74. H, 4 83, N, 9 10 The title compound was prepared, according to the procedure of Example 16 usmg 5-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6-yl)-2-fluoro- benzomtπle, as a white sohd mp 258-259°C, Η-NMR (DMSO-de) δ 12 3 (s, IH), 8 35-8 32 (m, IH), 8 15-8 10 (m, IH), 7 72-7 7 (m, 2H), 7 66-7 60 (m, IH), 7 13 (d, IH, J = 8 07 Hz), 1 7 (s, 6H), LC/MS (ES) m/z 311 ([M + H] + , 100%), Anal Calcd For C 17 H 13 FN 2 OS C, 64 99, H, 4 24, N, 8 66 Found C, 64 7, H, 4 09, N, 8 66 EXAMPLE 26 6-(5-Bromopyridin-3-yl)-4,4-dimethyl-l,4-dihvdro-2H-3,l-benzoxa-rine-2-thione 6-(5-Bromo-pyπdm-3-yl)-4,4-dιmethyl- 1 ,4-dιhydro-benzo [d] [ 1 ,3] oxazιn-2- one, prepared from (l,4-dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxm-6-yl)boromc acid and 3,5-dιbromopyndιne accordmg to the procedure of Example 6, as a white sohd mp 211-212°C, 'H-NMR (DMSO-de) δ 10 4 (s, IH), 8 92 (d, IH, J= 1 9 Hz), 8 66 (d, IH, J= 2 09 Hz ), 8 40 (t, IH, J= 2 02 Hz), 7 72-7 68 (m, 2H), 6 99 (d, IH, J= 8 1 Hz), 1 7 (s, 6H), MS (APCI) m/z 333([M + H] + , 100%), 335([M + H] + , 100%), Anal Calcd For Ci 5 H 13 BrN 2 O2 C, 54 07, H, 3 93, N, 8 41 Found C, 54 15, H, 3 89, N, 8 31 The title compound was prepared, accordmg to the procedure of Example 16 usmg 6-(5-bromo-pyπdm-3-yl)-4,4-dιmethyl- 1 ,4-dιhydro- benzo[d] [ 1 ,3]oxazιn-2-one, as a white sohd mp 252-253°C, Η-NMR (DMSO-d6) δ 12 3 (s, IH), 8 94 (s, IH), 8 69 (s, IH), 8 44 (s, IH), 7 78-7 76 (m, 2H), 7 14 (d, IH, J = 8 8 Hz), 1 7 (s, 6H), LC/MS (ES) m/z 347/349 ([M- H] ), Anal Calcd For C 15 H 13 BrN 2 OS C, 51 32, H, 3 79, N, 7 98 Found C, 50 95, H, 3 56, N, 7 72 EXAMPLE 27 6-(3-ChIoro-5-fluorophenyl)-4,4-dimethyl-l,4-dihvdro-2H-3,l-benzoxazine-2- thione 6-(3-Chloro-5-fluoro-phenyl)-4,4-drmethyl-l ,4-dιhydro-benzo [d] [ 1 ,3] oxazιn-2- one was prepared, from (l,4-dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxιn-6- yl)boronιc acid and l-bromo-3-chloro-5-fluorobenzene accordmg to the procedure of Example 5, as a white solid mp 193-194 °C, ] H-NMR (DMSO-de) δ 10 4 (s, IH), 7 67-7 64 (m, 3H), 7 61-7 57 (m, IH), 7 41-7 37 (m, IH), 6 96 (d, IH, J= 8 72 Hz), 1 7 (s, 6H), MS (APCI) m/z 306([M + H]\ 100%), Anal Calc For Cι 6 Hι 3 ClFN0 2 C, 62 86, H, 4 29, N, 4 58 Found C, 62 98, H, 4 1, N, 4 6 The title compound was prepared, accordmg to the procedure of Example 16, starting with 6-(3-chloro-5-fluoro-phenyl)-4,4-dιmethyl-l,4-dιhydro- benzo[d][l,3]oxazιn-2-one mp 204-205T, Η-NMR (CDC1 3 ) δ 10 0 (s, IH), 7 49 (m, IH), 7 31 (bs, 2H), 7 15-7 08 (m. 2H), 7 01 (d, IH, J= 8 23 Hz), 1 9 (s, 6H), LC/MS (ES) m/z 320/322 ([M- H] " ) EXAMPLE 28 6-(3-Bromo-5-methylphenyl)-4,4-dimethyl-l,4-dihydro-2H-3,l-benzoxazine-2- thione 6-(3-Bromo-5-methyl-phenyl)-4,4-dιmethyl-l,4-dιhydrobenzo-[d][l,3]oxazm- 2-one was prepared, usmg (4,4-dιmethyl-l,4-dιhydro-2-oxo-2H-3,l-benzoxazm-6- yl)boronιc acid and 3,5-dibromotoluene according to the procedure of Example 5, as a white sohd mp 231-233 °C, Η-NMR (DMSO-de) δ 10 4 (s, IH), 7 66 (s, IH), 7 58- 7 56 (m, 2H), 7 50 (s, IH), 7 37 (s, IH), 6 95 (d, IH, J= 8 67 Hz), 2 37 (s, 3H), 1 67 (s, 6H), MS (ESI) m/z 344/346 ([M-H] " , 100%), Anal Calc For Cι 7 H 16 BrNO 2 C, 58 98, H, 4 66, N, 4 05 Found C, 58 82, H, 4 62, N, 3 94 The title compound was prepared accordmg to the procedure of Example 16, usmg 6-(3-Bromo-5-methyl-phenyl)-4,4-dιmethyl- 1 ,4-dιhydro-benzo [d] [1 ,3] oxazιn-2- one, as ayellow solid mp 183-184°C, Η-NMR (CDC1 3 ) δ 9 8 (s, IH), 7 48-7 46 (m, 2H), 7 34-7 25 (m, 4H), 6 97 (d, IH, J= 8 2 Hz), 2 4 (s, 3H), 1 8 (s, 6H), MS (ES) m/z 360/362 ([M- H] " ) EXAMPLE 29 6-(3-Bromo-5-trifluorometho--yphenyl)-4,4-dimethyl-l,4-dihydro-2H-3,l- benzoxazine-2-thione 6-(3-Bromo-5-trιfluoromethoxy-phenyl)-4,4-dιmethyl- 1 ,4- dιhydrobenzo[d][l,3]-oxazm-2-one was prepared, usmg (4, 4-dιmethyl-l,4-dιhydro-2- oxo-2H-3,l-benzoxazιn-6-yι)boronιc acid and 1, 3-dιbromo-5- tnfluoromethoxybenzene accordmg to the procedure of Example 5, as a white sohd mp 214-216 °C, Η-NMR (DMSO-d 6 ) δ 10 4 (s, IH), 7 99 (s, IH), 7 73 (s, IH), 7 68- 7 62 (m, 3H), 6 97 (d, IH, J= 8 0 Hz), 1 68 (s, 6H), MS (ESI) m/z 414 ([M - H] , 100%), Anal Calc For C, 7 H, 3 BrF 3 N0 3 C, 49 06, H, 3 15, N, 3 37 Found C, 49 16, H, 3 05, N, 3 30 The title compound was prepared, accordmg to the procedure of Example 16 starting with 6-(3-Bromo-5-tnfluoromethoxy-phenyl)-4,4-dιmethyl-l ,4-dιhydro- benzo[d][l,3]oxazιn-2-one, as a yellow sohd mp 192-193°C, Η-NMR (CDC1 3 ) δ 9 4 (s, IH), 7 61 (s, IH), 7 49-7 46 (m, IH), 7 40 (s, IH), 7 30 (s, 2H), 6 96 (d, IH, J = 8 22 Hz) 1 9 (s, 6H), MS (ES) m/z 431/433 ([M- H] ) EXAMPLE 30 3-_ l,2-Dihvdro-2-thioxospiro.4H-3,l-benzoxazine-4,l-cvclohexanl-6-v-)-5- fluorobenzonitrile 3-(l, 2-Dιhydro-2-oxospιro[4H-3, l-benzoxazιne-4, l-cyclohexan]-6-yl)-5- fluorobenzonitπle was prepared, accordmg to the procedure of Example 5 from spiro- (4. -cyclohexane-l,4-dιhydro-2-oxo-2H-3,l-benzoxazm-6-yl) boromc acid and 3- bromo-5-fluorobenzonιtnle, as a white powder mp 250-253 °C, IR (KBr) 2220 cm 1 , 'H-NMR (DMSO-de) δ 10 34 (s, IH), 8 13 (s, IH), 8 0 (d, IH, J= 10 6 Hz), 7 80-7 7 (m, 3 H), 6 98-6 95 (d, IH, J= 8 1 Hz), 1 99-1 97 (m, 4H), 1 76-1 65 (m, 6H), 1 37- 1 33 (m IH) MS (El) m/z 336 (M * ), Anal Calc For C 20 H 17 FN 2 O 2 H 2 O C, 67 78, H, 5 40, N, 7 90 Found C, 67 9, H, 4 93, N, 7 67 The title compound was prepared, accordmg to the procedure of Example 16 usmg 3-(l,2-Dιhydro-2-oxospιro[4H-3,l-benzoxazme-4,l-cyclohexan]-6-yl)-5- fluorobenzomtnle mp 235-237°C, Η-NMR (CDC1 3 ) δ 10 0 (s, IH), 7 76-7 69 (m, 2H), 7 50-7 33 (m, 3H), 7 03 (d, IH, J= 8 8 Hz), 2 3-1 26 (m. 10H), MS (ES) m/z 351 ([M- H] ) EXAMPLE 31 3-.4,4-Dimethyl-2-thioxo-l,4-dihvdro-2H-3,l-benzoxa-rin-6-yl)-5- methylbenzonitrile 3-(4,4-Dιmethyl-2-oxo- 1 ,4-dιhydro-2H-benzo[d] [ 1 ,3] oxazm-6-yl)-5-methyl- benzonitnle was prepared, from (4, 4-dιmethyl-l,4-dιhydro-2-oxo-2H-3,l-benzoxazm- 6-yl)boronιc acid and 3-bomo-5-methylbenzomtπle accordmg to the procedure of Example 5, as a white solid mp 256-258 °C, Η-NMR (DMSO-de) δ 10 4 (s, IH), 7 99 (s, IH), 7 86 (s, IH), 7 67-7 62 ( , 3H), 6 97 (d, IH, J = 8 11 Hz), 2 42 (s, 3H), 1 68 (s, 6H), MS (APCI) m/z 293 ([M+H] + , 100%), Anal Calc For C 18 H 16 N 2 0 2 C, 73 96, H, 5 52, N, 9 58 Found C, 73 26, H, 5 46, N, 9 24 The title compound was prepared, accordmg to the procedure for Example 16 starting with 6-(3-cyano-5-methyl-phenyl]4 4-dιmethyl-l,4-dιhydro- benzo[d][l,3]oxazm-2-one mp 230-231°C, 'H-NMR (CDC1 3 ) δ 9 1 (S, IH), 7 61 (s, IH), 7 55 (s, IH), 7 50-7 47 (m, 2H), 7 32-7 31 (m, IH), 6 91 (d, IH, J= 8 2), 2 5 (s, 3H), 1 8 (s, 6H), MS (ES) m/z 307 ([M- H] ) EXAMPLE 32 6-(3,5-Dichlorophenyl)-4,4-dimethyl-l.ι4-dihvdro-2H-3.,l-benzoxazine-2-thione 6-(3,5-dιchloro-phenyl)-4,4-dιmethyl-l,4-dιhydrobenzo-[d][l,3]oxazm-2-one was prepared, from 6-bromo-4,4-dιmethyl-l,4-dιhydro-benzo[d][l,3]oxazιn-2-one and 3,5-dιchlorophenyl boromc acid accordmg to the procedure of Example 4, as a white sohd mp 245-246 °C, Η-NMR (DMSO-de) δ 10 4 (s, IH), 7 77 (m, 2H), 7 67-7 64 (m, 2H), 7 56 (bs, IH), 6 96 (d, IH, J = 7 98 Hz), 1 7 (s, 6H), MS (El) m/z 321 ([M+H] + , 40%), Anal Calc For C, 6 H 13 Cl 2 NO 2 C, 59 32, H, 4 11, N, 4 32 Found C. 59 13, H, 4 29, N, 4 17 The title compound was prepared, accordmg to the procedure of Example 16 startmg wιth 6-(3,5-Dιchloro-phenyl)-4,4-dιmethyl-l,4-dιhydro-benzo[d][l,3]oxazm- 2-one mp 206-208°C, Η-NMR (CDC1 3 ) δ 9 5 (s, IH), 7 49-7 45 (m, IH), 7 40-7 36 (m, 3H), 7 3-7 29 (m, IH), 6 95 (d, IH, J= 8 23), 1 8 (s, 6H), MS (ES) m/z 336/338 ([M- H] " ) EXAMPLE 33 WAY-164904; 5-(4,4-Dimethyl-l,2-thioxo-l,4-dihvdro-2H-3.1-benzoxazin-6- vDisophthalonitrile 5-(4,4-Dιmethyl-2-oxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6-yl)- isophthalonitπle was prepared from (l,4-dιhydro-4,4-dιmethyl-2-oxo-2H-3,l- benzoxm-6-yl)boromc acid and 5-bromoιsophthalomtnle accordmg to the procedure Example 5, as a white solid mp 288-289 °C, Η-NMR (DMSO-d 6 ) δ 10 4 (s, IH), 8 58 (s, 2H), 8 40 (d, IH, J= 0 77 Hz), 7 80-7 75 (m, 2H), 6 99 (d, IH, J= 8 2 Hz), 1 7 (s, 6H), MS (El) m/z 303([M"], 20%), Anal Calc For C 18 H 13 N 3 O 2 1 65 H 2 O C, 64 92, H, 4 93, N, 12 62 Found C, 64 74, H, 4 69, N, 12 32 The title compound was prepared according to the procedure of Example 16 starting with 5-(4,4-Dιmethyl-2-oxo-l ,4-dιhydro-2H-benzo[d] [1 ,3]oxazιn-6-yl)- lsophthalomtπle mp 240-242°C, Η-NMR (CDC1 3 ) δ 9 4 (s, IH), 8 03 (d, 2H, J = 1 25 Hz), 7 92 (s, IH), 7 50 (dd, IH, J= 8 22, 1 89 Hz), 7 33 (d, IH, J = 1 8 Hz), 7 01 (d, IH, J= 8 24 Hz), 1 84 (s, 6H), MS (ES) m/z 318 ([M- H] ) EXAMPLE 34 5-(4.4-Dimethyl-2-thioxo- 1 ,4-dih yd ro-2H-3, l-benzoxazin-6-yl)-2-furonitrile 5-(4,4-Dιmethyl-2-oxo- 1 ,4-dιhydro-2H-benzo [d] [ 1 ,3] oxazm-6-yl)-furan-2- carbomtπle was prepared, accordmg to the procedure of Example 5 from 2-bromo-5- cyanofuran (1 0 g, 5 6 mmol) (J Med Chem (1997), 40(23), 3804-3819) and (1,4- dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxazm-6-yl)boromc acid (1 8 g, 8 18 mmol), as a white sohd (0 39 g, 1 45 mmol, 17%) mp 257 - 260 °C, Η-NMR (DMSO-d 6 ) δ 1048 (s, IH), 7 73 - 7 70 (m, 3H), 7 19 (d, 1 H, J= 3 8 Hz), 6 98 (d, 1 H, J= 8 9 Hz), 1 66 (s, 6H), MS ((+)-APCI) m/z = 269 (M+H) + The title compound was prepared accordmg to the procedure of Example 16 usmg 5-( 1 ,4-Dιhydro-4,4-dιmethyl-2-oxo-2H-3 , 1 -benzoxazιn-6-yl)-2- furancarbonitπle mp 200°C decomposes, Η-NMR (CDC1 3 ) δ 9 1 (s, IH), 7 63 (dd, IH, J= 8 26, 1 68 Hz), 7 53 (d, IH, J= 1 59 Hz), 7 19 (d, IH, J= 3 7 Hz), 6 89 (d, IH, J= 8 31 Hz), 6 71 (d, IH, J= 3 72 Hz), 1 8 (s, 6H), MS (ES) m z 283 ([M- H] ) EXAMPLE 35 4,4-Diethyl-6-(3-nitrophenyl)-1.4-dihvdro-2H-3,l-benzoxazine-2-thione 4,4-Dιethyl-6-(3-mtrophenyl)- 1 ,4-dιhydrobenzo [d] [ 1 ,3] oxazιn-2-one was prepared, from 4,4-dιethyl-6-ιodo-l,4-dιhydrobenzo[d][l,3]oxazm-2-one and 3- mtrophenyl boromc acid accordmg to the procedure of Example 4, as an off- white sohd mp 193-194 °C, Η-NMR (CDC1 3 ) δ 9 19 (s, IH, D 2 0 exchangeable), 8 38 (t, IH. J= 1 9 Hz), 8 20 (m, IH), 7 83 (m, IH), 7 61 (t, IH, J=8 0 Hz), 7 50 (dd, IH, J = 8 2, 2 0 Hz), 7 23 (d, IH, J= 1 7 Hz), 6 99 (d, IH, J= 8 3 Hz), 2 09 (q, 4H, J = 7 4 Hz), 0 96 (t, 6H, J = 8 3 Hz), MS (El) m/z 325 ([M-H] , 100%) Anal Calc For C 18 Hι 8 N 2 O 4 -0 3 H 2 O C, 65 17, H, 5 65, N, 8 44 Found C, 65 31, H, 5 60, N, 8 10 The title compound was prepared, according to the procedure of Example 16 starting wιth 4,4-Dιethyl-6-(3-mtro-phenyl)-l,4-dιhydro-benzo[d][l,3]oxazm-2-one, as a yellow solid mp 180-181°C, Η-NMR (CDC1 3 ) δ 9 1 (s, IH), 8 38 (t, 1H, J = 1 94 Hz), 8 25-8 22 (m, IH), 7 87-7 85 (m, IH), 7 64 (t, IH, J= 7 99 Hz), 7 55 (dd, IH. J= 8 24, 1 89 Hz), 7 25 (d, IH, J= 1 71 Hz), 6 93 (d, IH, J= 8 25 Hz), 2 2-2 03 ( 4H), 0 96 (t, 6H, J= 7 33 Hz), MS (ES) m/z 341 ([M- H] ) EXAMPLE 36 6-(3-Chlorophenyl)-4-methyl-4-phenyl-l.,4-dihvdro-2H-3,l-benzoxazine-2-thione A mixture of 2-arnmo-5-bromo--V-methoxy--V-methylbenzamιde (7 78g, 30 mmol), 3-chlorophenyl boromc acid (5 63g, 36 mmol), tetrakιs(tnphenylphosphme)palladιum (0) (1 73g, 1 5 mmol), and sodium carbonate (7 63g, 72 mmol) in a mixture of DME and water (150 mL/30 mL) was degassed to remove the oxygen and heated at 85 °C under nitrogen for 3 hours The reaction mixture was cooled to room temperature and treated with brine (30 mL) and ethyl acetate (100 mL) The orgamc layer was separated and the aqueous layer was extracted with ethyl acetate (3x40 mL) The combmed orgamc layers were washed with brme and dried with MgS0 4 After removal of the solvent, the residue was purified by a flash chromatography (sihca gel, hexane ethyl acetate/1 1) to give 5-(3- chlorophenyl)--V-methoxy--V-methylbenzamιde as a brown oil (5g, 57%) To a solution of this benzamide (5g, 17 2 mmol) in anhydrous THF was added in a dropwise fashion a solution of methyllithium m ether (1 4M, 28 6 mL, 40 mL) at -78 °C under nitrogen After stirring for 30 minutes, the reaction mixture was treated with a saturated aqueous ammomum chlonde solution (50 mL) at -78 °C Ethyl acetate (100 mL) was added, orgamc layer was separated, and aqueous layer was extracted with ethyl acetate (3x20 mL) The combmed orgamc layers were washed (brme) and dned (MgS0 4 ) After removal of the solvent, the residue was punfied by a flash chromatography (sihca gel, hexane ethyl acetate/2 1) to afford l-(4-amιno-3'-chloro- bιphenyl-3-yl)-ethanone as a yellow solid (2g, 47%) mp 89-90 °C, Η-NMR (CDC1 3 ) δ 7 89 (d, IH, J= 2 0 Hz), 7 51 (m, 2H), 7 25-7 40 (m, 3H), 6 73 (d, IH, J= 8 6 Hz), 6 38 (br, 2H), 2 65 (s, 3H), MS (El) m/z 268([M+Na] + , 60%), Anal Calc For C, 68 44, H, 4 92, N, 5 70 Found C, 68 40, H, 4 89, N, 5 61 6-(3-Chlorophenyl)-4-methyl-4-phenyl-l ,4-dιhydro-benzo[d] [ 1 ,3]oxazιn-2-one was prepared, from l-(4-ammo-3'-chloro-biphenyl-3-yl)-ethanone (0 2g, 0 82 mmol) and phenylmagnesium bromide followed by treatment with CDI m THF, as a white sohd mp 179-180 °C, Η-NMR (CDC1 3 ) δ 8 27 (s, IH, D 2 O exchangeable), 7 51-7 57 (m, 2H), 7 28-7 45 (m, 9H), 6 92 (d, IH, J= 8 4 Hz), 2 12 (s, 3H), MS (ESI) m/z 348 ([M-H] " , 100%), Anal Calc For C 2 ιH, 6 ClNO 2 C, 72 10, H, 4 61, N, 4 00 Found C. 71 72, H, 4 86, N, 3 91 The title compound was prepared, accordmg to the procedure of Example 16 startmg with 6-(3-chlorophenyl)-4-methyl-4-phenyl-l,4-dιhydro-benzo[d][l,3]oxazm- 2-one, as a white sohd mp 202-203°C, Η-NMR (CDC1 3 ) δ 8 9 (s, IH), 7 59-7 56 (m, 2H), 7 49-7 30 (m, 9H), 6 91 (d, IH, J= 8 19 Hz), 2 2 (s, 3H), MS (ES) m/z 364 ([M- H] ) EXAMPLE 37 4-AUyl-6-(3-chlorophenyl)-4-methyl-l,4-dihydro-2H-3 -benzoxa-rine-2-thione To a solution of l-(4-am-no-3'-chloro-bιphenyl-3-yl)-ethanone (0 2g, 0 82 mmol) m anhydrous THF (10 mL) was added a solution of allylmagnesium bromide in ether (1 0 M, 3 mL, 3 mmol) at 0°C under nitrogen The reaction solution was slowly warmed to ambient temperature and stuτed under mtrogen for 1 hour A saturated aqueous ammomum chlonde solution (10 mL) was added and was followed by addition of ethyl acetate (50 mL) The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3x10 mL) The combmed organic layers were washed with brme and dned with MgS0 4 After removal of solvent, the residue was purified by a flash chromatography (sihca gel, hexane ethyl acetate/3 1) to afford an ammo carbmol mtermediate which was used m next step without further purification To a solution of the above ammo carbmol m anhydrous THF was added CDI (0 38g, 2 3 mmol) at ambient temperature under nitrogen The reaction solution was heated at 55 °C for 12 hours and then cooled to room temperature The solvent was removed in vacuo and the residue was puπfied by a flash chromatography (sihca gel, hexane ethyl acetate/2 1) to yield 4-allyl-6-(3-chlorophenyl)-4-methyl-l,4-dιhydro- benzo[d][l,3]oxazιn-2-one as a white sohd (130 mg, 52%) mp 128-129 °C, Η-NMR (CDC1 3 ) δ 8 68 (s, IH, D 2 0 exchangeable), 7 50 (s, IH), 7 44 (dd, IH, J- 8 2, 1 9 Hz), 7 31-7 40 (m, 3H), 7 25 (d, IH, J= 1 6 Hz), 6 92 (d, IH, J= 8 2 Hz), 5 70-5 85 (m, IH), 5 17 (m, 2H), 2 76 (m, 2H), 1 79 (s, 3H), MS (ESI) m/z 314 ([M+H] + , 40%), Anal Calc For C 18 H 16 ClNO 2 C, 68 90, H, 5 14, N, 4 46 Found C, 68 90, H, 5 18, N, 4 43 The title compound was prepared accordmg to the procedure of Example 16 startmg with 4- Allyl-6-(3-chloro-phenyl)-4-methyl-l,4-d-hydro-benzo[d][l,3]oxazm-2- one mp 150-151°C, ] H-NMR (CDC1 3 ) δ 8 9 (s, IH), 7 50-7 47 (m, 2H), 7 40-7 35 (m, 3H), 7 27 (s, IH), 6 87 (d, IH, J= 8 22 Hz), 5 81-5 72 (m, IH), 5 19-5 13 (m, 2H), 2 78-2 75 (m, 2H), 1 82 (s, 3H), MS (ES) m/z 328 ([M- H] ) EXAMPLE 38 3-Chloro-5-(4,4-dimethyl-2-thioxo-l,4-dihvdro-2H-3,l-benzoxazin-6- vDbenzonitrile 3-Chloro-5-(4,4-dιmethyl-2-oxo- 1 ,4-dιhydro-2H-benzo[d] [ 1 ,3] oxazιn-6-yl)- benzomtnle was prepared, from (l,4-dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxιn-6- yl)boronιc acid and l-bromo-3-chlorobenzomtπle accordmg to the procedure of Example 5, as a white solid mp 256-257 °C, Η-NMR (DMSO-de) δ 10 4 (s, IH), 8 22 (bs, IH), 8 15 (bs, IH), 7 98 (bs, IH), 7 74-7 71 (m, 2H), 6 97 (d, IH, J= 8 09 Hz), 1 7 (s, 6H), MS (ESI) m/z 311([M - H] , 100%), Anal Calc For C I7 H 13 CIN 2 O 2 C, 65 29, H, 4 19, N, 8 96 Found C, 65 25, H, 3 92, N, 8 71 The title compound was prepared accordmg to the procedure of Example 16 startmg with 3-chloro-5-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6- yl)-benzomtπle mp 249-251°C, Η-NMR (CDC1 3 ) δ 9 7 (s, IH), 7 74-7 73 (m, IH), 7 71-7 70 (m, IH), 7 64-7 63 ( , IH), 7 48 (dd, IH, J= 8 24, 1 86 Hz), 7 3 (d, IH, J = 1 73 Hz), 7 01 (d, IH, J= 8 24 Hz), 1 8 (s, 6H), MS (ES) m/z 327/329 ([M- H] ) EXAMPLE 39 6-(3,5-Difluorophenyl)-4,4-dimethyl-l,4-dihvdro-2H-3J-benzoxa--ine-2-thione 6-(3,5-dιfluoro-phenyl)-4,4-dιmethyl- 1 ,4-dιhydrobenzo-[d] [ 1 ,3]oxazιn-2-one was prepared, accordmg to the procedure of Example 5 from (4,4-dιmethyl-l,4- dιhydro-2-oxo-2H-3,l-benzoxazm-6-yl)boromc acid and l-bromo-3,5- difluorobenzene, as a white solid mp 218-219 °C, Η-NMR (DMSO-d 6 ) δ 10 4 (s, IH), 7 67-7 65 (m, 2H), 7 49 (d, 2H, J= 7 73 Hz), 7 19 (t, IH, J= 9 29 Hz), 6 96 (d, IH, J= 8 88 Hz), 1 7 (s, 6H), MS (APCI) m/z 290 ([M + H] + , 100%), Anal Calc For C,eH 13 F 2 N0 2 C, 66 43, H, 4 53, N, 4 84 Found C, 66 01, H, 4 46, N, 4 67 The title compound was prepared accordmg to the procedure of Example 16 startmg with 6-(3, 5-Dιfluoro-phenyl)-4,4-dιmethyl- 1 ,4-dιhydro-benzo [d] [ 1 ,3] oxazin- 2-one mp 224-225°C, 'H-NMR (CDC1 3 ) δ 9 7 (S, IH), 7 48 (dd, IH, J= 8 16, 1 74 Hz), 7 31 (d, IH, J= 1 66 Hz), 7 08-7 03 (m, 2H), 6 98 (d, IH, J = 8 23 Hz), 6 85- 6 78 (m, IH) 1 8 (s, 6H), MS (ES) m/z 304 ([M- H] ) EXAMPLE 40 6-(3-Fluoro-5-methoxyphenyl)-4,4-dimethyl-l,4-dihvdro-2H-3,l-benzoxazine-2- thione 6-(3-Fluoro-5-methoxy-phenyl)-4,4-dιmethyl-l,4-dιhydro- benzo[d][l,3]oxazιn-2-one was prepared, from (l,4-dιhydro-4,4-dιmethyl-2-oxo-2H- 3,l-benzoxιn-6-yl)boronιc acid and 3-bromo-5-fluoroamsole accordmg to the procedure of Example 5, as a white solid mp 181-182 °C, Η-NMR (DMSO-de) δ 10 4 (s, IH), 7 62-7 59 (m, 2H), 7 13-7 06 (m, 2H), 6 97-6 94 (d, IH, J= 8 89 Hz), 6 80 (dt, IH, J= 10 95, 2 12 Hz), 3 8 (s, 3H), 1 7 (s, 6H), MS (ESI) m/z 302 ([M + H] + , 100%), Anal Calc For Cι 7 H 16 FN0 3 0 1 H 2 0 C, 67 36, H, 5 39, N, 4 62 Found C, 67 11, H, 5 44, N, 4 48 The title compound was prepared, accordmg to the procedure of Example 16 startmg with 6-(3-fluoro-5-methoxy-phenyl)-4,4-dιmethyl-l,4-dιhydro- benzo[d][l,3]oxazιn-2-one, as a white sohd mp 170-171°C, ] H-NMR (CDC1 3 ) δ 9 2 (s. IH), 7 48 (dd, IH, J= 8 18, 1 84 Hz), 7 32 (d, IH, J= 1 66 Hz), 6 91 (d, IH, J = 8 23 Hz), 6 84 (d, IH, J= 2 11 Hz), 6 82-6 81 (m, IH), 6 66-6 61 (m, IH), 3 9 (s, 3H), 1 8 (s, 6H), MS (ES) m/z 316 ([M- H] ) EXAMPLE 41 3-(4,4-Dimethyl-2-thioxo-l,4-dihvdro-2H-3,l-benzoxazin-6-yr_-5- methoxybenzonitrile A mixture of (4,4-dιmethyl- 1 ,4-dιhydro-2-oxo-2H-3 , 1 -benzoxazιn-6-yl)boronιc acid (4 2 g, 19 0 mmol), 3-cyano-5-methoxybenzyltπflate (5 1 g, 19 0 mmol), tetratos(tnphenylphosphιne)-palladιum (0) (1 1 g, 0 95 mmol), sodium carbonate (4 0 g. 38 0 mmol), hthium bromide (5 g, 57 mmol) in DME (50 mL), and water (25 mL) under a blanket of nitrogen, was stiπed for 15 mmutes at 50 °C This solution was then was heated at 85 °C for 1 hour The reaction mixture was cooled to room temperature and ethyl acetate (100 mL) was added The orgamc layers were washed twice with aqueous ammonium chlonde (100 mL) and once with brme (100 mL), dned over magnesium sulfate and concentrated Purification via chromatography (sihca gel, 40% ethyl acetate/ hexane) gave 3-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H- benzo[d][l,3]oxazm-6-yl)-5-methoxy-benzonιtnle as a white sohd (0 69 g 53%) mp 254-255 °C, Η-NMR (DMSO-de) δ 10 4 (s, IH), 7 84 (s, IH), 7 67-7 61 (m, 2H), 7 55 (bs, IH), 7 4 (bs IH) 6 99 (d, IH, J= 7 94 Hz), 3 88 (s, 3H), 1 67 (s, 6H, ), MS (El) m/z 308 ([M + H] + , 30%), Anal Calc For Cι 8 H, 6 N 2 0 3 C, 68 13, H, 5 40, N, 8 83 Found C, 68 03, H, 5 22, N, 8 46 The title compound was prepared, accordmg to the procedure of Example 16 startmg with 3-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6-yl)-5- methoxy-benzomtπle, as an off-white sohd mp 201-202°C, Η-NMR (CDC1 3 ) δ 9 1 (s, IH), 7 48 (dd, 1H, J= 8 16, 1 8 Hz), 7 41 (s, IH), 7 31 (d, 1H, J= 1 69 Hz), 7 27 (m, IH), 7 14 (m, IH), 6 92 (d, IH, J= 8 2 Hz), 3 9 (s, 3H), 1 8 (s, 6H), MS (ES) m/z 323 ([M- H] ) EXAMPLE 42 6-(3-Fluorophenyl)-4.,4-dimethyl-1.4-dihvdro-2H-3,l-benzox--zine-2-thione 6-(3-Fluoro-phenyl)-4,4-dιmethyl- 1 ,4-dιhydro-benzo[d] [ 1 ,3]oxazιn-2-one was prepared, from 6-bromo-4,4-dιmethyl-l,4-dιhydro-benzo[d][l,3]oxazm-2-one 1- bromo-3-fluoro benzene accordmg to the procedure of Example 4, as a hght yellow sohd mp 181-182 °C, Η-NMR (DMSO-de) δ 10 4 (s, IH), 7 62-7 44 (m, 5H), 7 16 (t, IH, J= 2 22 Hz), 6 97 (d, IH, J= 8 83), 1 67 (s, 6H), MS (El) m/z 271 ([M + Hf, 40%), Anal Calc For Cι 6 H 14 FNO 2 C, 69 91, H, 5 3, N, 5 1 Found C, 70 0, H. 5 32, N, 4 92 The title compound was prepared, accordmg to the procedure of Example 16 usmg 6-(3-Fluoro-phenyl)-4,4-dιmethyl-l,4-dιhydro-benzo[d][l,3]oxazm-2-one, as a white sohd mp 194-195°C, Η-NMR (CDC1 3 ) δ 8 9 (s, IH), 7 50 (dd, IH, J= 8 15, 1 73 Hz), 7 46-7 38 (m, IH), 7 34-7 30 (m, 2H), 7 25-7 21 (m, IH), 7 10-7 04 (m, IH), 6 89 (d, IH, J= 8 21 Hz), 1 8 (s, 6H), MS (ES) m/z 286 ([M- H] ) EXAMPLE 43 6-[3-Fluoro-5-(trifluoromethyl)phenyI1-4,4-dimethyl-l,4-dihvdro-2H-3.,l- benzoxazine-2-thione 6-(3-Fluoro-5-tπfluoromethyl-phenyl)-4,4-dιmethyl- 1 ,4-dιhydro- benzo[d][l,3]oxazιn-2-one was prepared from (1.4-dιhydro-4,4-dιmethyl-2-oxo-2H- 3,l-benzoxm-6-yl)boromc acid and l-bromo-3-fluoro-5-tnfluoromethylbenzene accordmg to the procedure of Example 5, as a white sohd mp 207-208 °C, Η-NMR (DMSO-de) δ 10 4 (s, IH), 7 94-7 9 (m, 2H), 7 73-7 7 (m, 2H), 7 63 (d, IH, J= 8 58 Hz), 6 99 (d, IH, J= 8 68 Hz), 1 7 (s, 6H), MS (El) m/z 339([M * ], 60%), Anal Calc For Cι 7 H 13 F 4 N0 2 C, 60 18, H, 3 86, N, 4 13 Found C, 59 9, H, 3 99, N, 4 06 The title compound was prepared, accordmg to the procedure of Example 16 startmg with 6-(3-fluoro-5-tπfluoromethyl-phenyl)-4,4-dιmethyl- 1 ,4-dιhydro- benzo[d][l,3]oxazιn-2-one, as a white sohd mp 204-206°C, 'H-NMR (CDC1 3 ) δ 9 2 (s, IH), 7 56 (s, IH), 7 5 (dd, IH, J= 8 14,1 97 Hz), 7 44-7 38 (m, IH), 7 36-7 30 (m, 2H), 6 92 (d, IH, J= 8 14 Hz), 1 83 (s, 6H), MS (ES) m/z 354 ([M- H] ) EXAMPLE 44 6-(2-Fluorophenyl)-4,4-dimethyl-l,4-dihydro-2H-3,l-benzoxazine-2-thione 6-(2-Fluoro-phenyl)-4,4-dιmethyl- 1 ,4-dιhydro-benzo[d] [1,3] oxazιn-2-one was prepared, accordmg to the procedure of Example 5 from (l,4-dιhydro-4,4-dιmethyl-2- oxo-2H-3,l-benzoxιn-6-yl)boronιc acid and l-bromo-2-fluoro benzene, as off-white crystals mp 164-165 °C, 1 H-NMR(DMSO-d 6 ) δ 10 33 (s, IH), 7 56 (m, IH), 7 25- 7 45 (m, 4H), 6 98 (d, IH, J = 8 7 Hz), 1 64 (s, 6H) The title compound was prepared, accordmg to the procedure of Example 16 startmg with 6-(2-fluoro-phenyl)-4,4-dιmethyl-l ,4-dιhydro-benzo [d] [ 1 ,3] oxazιn-2-one, as a white sohd mp 171-173°C, Η-NMR (CDC1 3 ) δ 8 97 (s, IH), 7 5-7 13 (m, 6H), 6 88 (d, IH, J= 8 14 Hz), 1 80 (s, 6H), MS (ES) m/z 286 ([M- H] ) EXAMPLE 45 6-(3.4-Difluorophenyl)-4,4-dimethyl-l,4-dihvdro-2H-3,l-benzoxazine-2-thione 6-(3,4-Dιfluoro-phenyl)-4,4-dιmethyl-l,4-dιhydro-benzo[d][l,3]oxazm-2-one was prepared, accordmg to the procedure of Example 5 from (l,4-dιhydro-4,4- dιmethyl-2-oxo-2H-3,l-benzoxιn-6-yl)boronιc acid and l-bromo-3, 4-drfluorobenzene, as off-white ciystals mp 207-208 °C, Η-NMR(DMSO-de) δ 10 35 (s, IH), 7 79 (m, IH), 7 40-7 63 (m, 4H), 6 95 (d, IH, J= 8 9 Hz), 1 62 (s, 6H) The title compound was prepared, accordmg to the procedure of Example 16 startmg with 6-(3,4-dιfluoro-phenyl)-4,4-dιmethyl- 1 ,4-dιhydro-benzo [d] [ 1 ,3] oxazιn-2- one, as a yellow solid mp 209-211°C, Η-NMR (CDC1 3 ) δ 8 94 (s, IH), 7 44 (dd, IH, J= 8 35, 1 98 Hz), 7 36-7 22 (m, 4H), 6 87 (d, IH, J= 8 35 Hz), 1 81 (s, 6H), MS (ES) m/z 304 ([M- H] ) EXAMPLE 46 6-(4-Fluorophenyl)-4,4-dimethyl-l,4-dihvdro-2H-3,l-benzoxa-rine-2-thione 6-(4-Fluoro-phenyl)-4,4-dιmethyl-l,4-dιhydro-benzo[d][l,3]oxazm-2-one was prepared, accordmg to the procedure of Example 5 from (l,4-dιhydro-4,4-dιmethyl-2- oxo-2H-3,l-benzoxιn-6-yl)boronιc acid and l-bromo-4-fluorobenzene, as off-white crystals mp 232-233 °C, Η-NMR (DMSO-dg) δ 10 3 (s, IH), 7 74 (m, 2H), 7 53 (m, 2H), 7 28 (m, 2H), 6 96 (d, IH, J = 8 9 Hz), 1 63 (s, 6H) The title compound was prepared, accordmg to the procedure of Example 16 startmg with 6-(4-fluoro-phenyl)-4,4-dιmethyl- 1 ,4-dιhydro-benzo[d] [ 1 ,3] oxazm-2-one, as a white sohd mp 221-223°C, Η-NMR (CDC1 3 ) δ 8 98 (s, IH), 7 5-7 44 (m, 3H), 7 5 (m, IH), 7 17-7 10 (m, 2H), 6 87 (d, IH, J= 8 14 Hz), 1 81 (s, 6H), MS (ES) m/z 286 ([M- H] ) EXAMPLE 47 3-(4,4-Dimethyl-2-thioxo-l,4-dihydro-2H-3,l-benzoxa-rin-6-yr,-4- fluorobenzonitrile 3-(4,4-Dιmethyl-2-oxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6-yl)-4-fluoro- benzonitnle was prepared, from (1, 4-dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxιn-6- yl)boronιc acid and 5-bromo-2-fluorobenzonιtπle accordmg to the procedure of Example 5, as a white sohd mp 229-230 °C, 'H-NMR (DMSO-de) δ 10 4 (s, IH), 8 15 (dd, 1H. J = 7 39, 2 12 Hz), 7 95-7 89 (m, IH), 7 59-7 48 (m, 3H), 6 99 (d, IH, J= 8 1 Hz) 1 7 (s, 6H), MS (APCI) m/z 297 ([M + H] + , 100%), Anal Calc For Cι 7 H ]3 FN 2 0 2 C, 68 91, H, 4 42, N, 9 45 Found C, 68 74, H, 4 83, N, 9 10 The title compound was prepared, accordmg to the procedure of Example 16 starting with 3-(4,4-dιmethyl-2-oxo- 1 ,4-dιhydro-2H-benzo[d] [ 1 ,3] oxazιn-6-yl)-4- fluoro-benzonitπle, as a yellow solid mp 250-251°C, Η-NMR (CDC1 3 ) δ 8 83 (s, IH), 7 73 (dd, 1H, J = 8 34, 2 19 Hz), 7 68-7 64 (m, IH), 7 48-7 44 (m, IH), 7 32-7 28 (m, 2H), 6 9 (d, IH, J = 8 34 Hz), 1 81 (s, 6H), MS (ES) m/z 311 ([M- H] ) EXAMPLE 48 6-f2.3-Difluorophenyl)-4,4-dimethyl-l,4-dihvdro-2H-3.1-benzoxazine-2-thione 6-(2,3-Dιfluoro-phenyl)-4,4-dιmethyl-l,4-dιhydro-benzo[d][l,3]oxazm-2-one was prepared, accordmg to the procedure of Example 5 from (1 ,4-dιhydro-4,4- dιmethyl-2-oxo-2H-3,l-benzoxazιn-6-yl)boronιc acid and 2,3-dιfluorobenzyltπflate, as a yellow sohd mp 166-167 °C, Η-NMR (DMSO-d 6 ) δ 10 4 (s, IH), 7 5-7 2 (m, 5H), 7 0 (m, IH), 1 7 (s, 6H), MS (El) m/z 289 ([M+H] + ), Anal Calc For C 16 H 13 F 2 NO 2 C, 66 43, H, 4 53, N, 4 84 Found C, 66 15, H, 4 37, N, 4 64 The title compound was prepared, accordmg to the procedure of Example 16 startmg with 6-(2,3-dιfluoro-phenyl)-4,4-dιmethyl-l,4-dιhydro-benzo[d][l,3]oxazm-2- one, as a white sohd mp 197-198°C, ] H-NMR (CDC1 3 ) δ 9 02 (s, IH), 7 49-7 45 (m, IH), 7 34 (s, IH), 7 2-7 13 (m, 3H), 6 9 (d, IH, J= 8 14 Hz), 1 80 (s, 6H), MS (ES) EXAMPLE 49 3-(8-Bromo-4,4-dimethyl-2-thioxo-1.4-dihvdro-2H-3,l-benzoxazin-6-vI)-5- flu orobenzonitrile To a mixture of 3-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-3,l-benzoxazιn-6-yl)- 5-fluorobenzonιtnle (0 5g, 1 7 mmol) and sodium acetate (0 2g, 2 4 mmol) in acetic acid (5 mL) was added, at room temperature under nitrogen, bromine (0 12 mL, 2 34 mmol) The reaction mixture was stirred for 20 hours and then poured mto ice water (30 mL) The precipitate was collected on a filter and washed with water (3x5 mL) to yield 3-(8-bromo-4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-3,l-benzoxazm-6-yl)-5- fluorobenzomtnle as an off-white sohd (0 48g, 75%) mp 216-217 °C, , Η-NMR (OMSO-d 6 ) δ 9.78 (s, IH), 8.18 (t, IH, J= 1.6 Hz), 8.02-8.08 (m, 2H), 7.81 (m, IH), 7.75 (d, 1H, J= 1.8 Hz), 1.66 (s, 6H). MS (ESI) m/z 373, 375 [M - H] " . The title compound was prepared according to the procedure of Example 16 starting with 3-(8-bromo-4,4-dimethyl-2-oxo- 1 ,4-dihydro-2H-3 , 1 -benzoxazin-6-yl)-5- fluorobenzonitrile: mp 219-220°C; Η-NMR (CDC1 3 ) δ 9.05 (s, IH), 7.70 (d, IH, J = 1.98 Hz), 7.6 (m, IH), 7.48-7.44 (m, IH), 7.4-7.36 (m, IH), 7.26 (m, IH), 1.80 (s, 6H); MS (ES) m/z 304 ([M- H] ). EXAMPLE 50 4.4-Dimethyl-6-(3-nitrophenvI)-l,4-dihvdro-2H-3,l-benzoxazine-2-thione 4,4-Dimethyl-6-(3-nitrophenyl)-l,4-dihydrobenzo[d][l,3]oxazin-2-one was prepared, fiOm 6-iodo-4,4-dimethyl-l,4-dihydro-benzo[d][l,3]oxazin-2-one and 3- nitrophenyl boronic acid according to the procedure of Example 4, as a yellowish solid: mp 244-245 °C; 'H-NMR (DMSO-de) δ 10.38 (s, IH, D 2 O exchangeable), 8.47 (s, IH), 8.14-8.20 (m, 2H), 7.70-7.76 (m, 3H), 7.01 (d, IH, J- 8.1 Hz), 1.68 (s, 6H); MS (El) m/z 297([M-H] " , 100%); Anal. Calc. For C, 6 H 14 N 2 O 4 : C, 64.42, H, 4.73, N, 9.39. Found: C, 63.93, H, 4.91, N, 8.71. The title compound was prepared, according to the procedure of Example 16 starting with 4,4-dimethyl-6-(3-nitro-phenyl)-l ,4-dihydro-benzo[d] [1 ,3]oxazin-2-one, as a yellow solid: mp 224-226°C; Η-NMR (CDC1 3 ) δ 8.89 (s, IH), 8.40 (s, IH), 8.26- 8.22 (m, IH), 7.88-7.86 (m, IH), 7.64 (t, IH, J= 7.97 Hz), 7.57 (dd, IH, J = 8.21, 1.3 Hz), 7.40 (m, IH), 6.94 (d, IH, J= 8.22 Hz), 1.80 (s, 6H); MS (ES) m/z 313 ([M- H] ). EXAMPLE 51 6-f3-Chlorophenyl)-4 < 4-diethyl-l,4-dihvdro-2H-3,l-benzoxazine-2-thione 6-(3-Chlorophenyl)-4,4-diethyl- 1 ,4-dihydrobenzo [d] [1,3] oxazin-2-one was prepared, from4,4-diethyl-6-iodo-l,4-dihydrobenzo[d][l,3]oxazin-2-one and 3- chlorophenyl boronic acid according to the procedure of Example 4, as a white sohd: mp 150-151 °C; Η-NMR (CDC1 3 ) δ 8.52 (s, IH, D 2 0 exchangeable), 7.50 (s, IH), 7.31-7.44 (m, 4H), 7.16 (d, IH, J= 1.5 Hz), 6.89 (d, IH, J= 8.2 Hz), 2.03 (m, 4H), 0 94 (t, 6H, J= 7 4 Hz), MS (El) m/z 315 (M", 53%) Anal Calc For C, 8 H 18 C1N0 2 C, 68 46, H, 5 75, N, 4 44 Found C, 68 16, H. 5 81, N, 4 32 The title compound was prepared, accordmg to the procedure of Example 16 startmg with 6-(3-chloro-phenyl)-4,4-dιethyl-l ,4-dιhydro-benzo[d] [1 ,3]oxazιn-2-one, as a white sohd mp 148-150°C, 'H-NMR (CDC1 3 ) δ 9 27 (s, IH), 7 50-7 45 (m, 2H), 7 40-7 34 (m, 3H), 7 17 (d, IH, J = 1 64 Hz), 6 94 (d, IH, J= 8 22 Hz), 2 18-2 01 (m, 4H), 0 94 (t, 6H, J = 7 33 Hz), MS (ES) m/z 303/332 ([M- H] ) EXAMPLE 52 6-(3-Methoxyphenyl)-4,4-dimethyl-l,4-dihvdro-2H-3,l-benzoxazine-2-thione 6-(3-Methoxy-phenyl)-4,4-dιmethyl- 1 ,4-dιhydro-benzo [d] [ 1 ,3] oxazιn-2-one was prepared, accordmg to the procedure of Example 4 from 6-bromo-4,4-dιmethyl- l,4-dιhydro-benzo[d][l,3]oxazm-2-one and 3-methoxyphenyl boronic acid, as a yellow sohd mp 164-165 °C, Η-NMR (DMSO-d 6 ) δ 10 3 (s, IH), 7 56 (m, 2H), 7 36 (t, 1 H, J= 7 89 Hz), 7 20 (m, 2H), 6 96 (d, IH, J= 8 88 Hz), 6 91 (dd, IH, J= 8 13, 2 35 Hz), 3 8 (s, 3H), 1 7 (s, 6H), MS (ESI) m/z 284 ([M+H] + , 30%), Anal Calc For C 17 H 17 NO 3 C, 72 07, H, 6 05, N, 4 94 Found C, 70 58, H, 5 73, N, 4 67 The title compound was prepared, accordmg to the procedure of Example 16 startmg with 6-(3 -Methoxy-phenyl)-4,4-dιmethyl- 1 ,4-dιhydro-benzo [d] [ 1 ,3] oxazιn-2- one, as a white sohd mp 142-143°C, Η-NMR (CDC1 3 ) δ 8 96 (s, IH), 7 51 (dd, IH, J = 8 2, 1 84 Hz), 7 40-7 35 (m, 2H), 7 13-7 10 (m. IH), 7 05 (t, IH, J= 2 21 Hz), 6 90 (dd, IH, J= 8 09, 2 46 Hz), 6 87 (d, IH, J= 8 2 Hz), 3 87 (s, 3H), 1 8 (s, 6H), MS (ES) m/z 298 ([M- H] ) EXAMPLE 53 6-(2-Chlorophenyl)-4,4-dimethyl-l,4-dihvdro-2H-3,l-benzoxazine-2-thione 6-(2-Chloro-phenyl)-4,4-dιmethyl-l,4-dιhydro-benzo[d][l,3]oxazm-2-one was prepared, accordmg to the procedure of Example 4 from 6-bromo-4,4-dιmethyl-l,4- dιhydro-benzo[d][l,3]oxazιn-2-one and 2-chlorophenyl boronic acid, as a white solid mp 181-182 °C, MS (ESI) m/z 288 ([M+H] + , 70%), Anal Calc For Cι 6 H 14 ClNO 2 C. 66 79, H, 4 90, N, 4 87 Found C, 66 78, H. 4 82, N, 4 55 The title compound was prepared, accordmg to the procedure of Example 16 startmg with 6-(2-chloro-phenyl)-4,4-dιmethyl- 1 ,4-dιhydro-benzo[d] [ 1 ,3] oxazm-2- one, as a white solid mp 171-172°C, Η-NMR (CDC1 3 ) δ 8 95 (s, IH), 7 51-7 47 (m. IH), 7 40-7 27 (m, 5H), 6 87 (d, IH, J= 8 14 Hz), 1 79 (s, 6H), MS (ES) rnz 302/304 ([M- H] ) EXAMPLE 54 4-Benzyl-6-(3-chlorophenyl)-4-methyl-1.4-dihvdro-2H-3,l-benzoxazine-2-thione A mixture of l-(4-amιno-3 -chloro-bιphenyl-3-yl)-l-benzyl-ethanol (prepared from l-(4-ammo-3'-chloro-bιphenyl-3-yl)-ethanone and benzylmagnesium bromide accordmg to procedure descπbed previously, 0 14 g, 0 42 mmol) and tπphosgene (0 04 g, 0 14 mmol) m dry THF (10 mL) was stirred under a blanket of mtrogen for 10 mmutes THF was removed and the residue purified via flash chromatography (silica gel, 35% ethyl acetate/hexane) to give 4-benzyl-6-(3-chloro-phenyl)-4-methyl-l,4- dιhydro-benzo[d][l,3]oxazm-2-one (0 045 g, 30%) as an off-white sohd mp 187-188 °C, Η-NMR (DMSO-de) δ 10 1 (s, IH), 7 70 (t, IH, J = 2 3 Hz), 7 6 (d, IH. J = 8 0 Hz), 7 58-7 53 (m, 2H), 7 46 (t, IH, J = 8 0 Hz), 7 38 (d, IH, J- 8 0 Hz), 7 22-7 17 (m, 3H), 7 06-7 0 (m, 2H), 6 84 (d, IH, J = 9 14 Hz), 3 24 (d, IH, J= 14 3 Hz), 3 06 (d, IH, J = 14 3 Hz), 1 68 (s, 3H), MS (ESI) m/z 364 ([M+H] + , 100%), Anal Calc For C 22 H ]8 ClN0 2 C, 72 63, H, 4 99, N, 3 85 Found C, 71 82, H, 5 09, N,3 58 The title compound was prepared, accordmg to the procedure of Example 16 startmg with 4-benzyl-6-(3-chloro-phenyl)-4-methyl- 1 ,4-dιhydro-benzo [d] [1.3] oxazin- 2-one, as a white sohd Η-NMR (CDC1 3 ) δ 9 09 (s, IH), 7 63 (dd, IH, J= 8 03, 1 83 Hz), 7 38-7 22 (m, 7H), 7 04-6 97 (m, 3H), 6 83 (d, IH, J= 8 22 Hz), 3 22 (s. 2H), 1 86 (s, 3H), MS (ES) m/z 378/380 ([M- H] ) EXAMPLE 55 6-(3-Bromo-5-fluorophenyl)-4« -dimethyl-l,4-dihvdro-2H-3,l-benzoxazine-2- thione 6-(3-Bromo-5-fluorophenyl)-4,4-dιmethyl-l,4-dιhydrobenzo[d][l,3]oxazm-2- one was prepared, from (l,4-dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxazm-6- yl)boronιc acid and l,3-dιbromo-5-fluorobenzene followmg the procedure of Example 5. as a white solid mp 182-183 °C, Η-NMR (DMSO-de) δ 10 36 (s, IH, D 2 0 exchangeable), 7 78 (s, IH), 7 58-7 65 (m, 3H), 7 49 (dd, IH, J= 8 3, 1 8 Hz), 6 96 (d. IH, J= 8 5 Hz), 1 69 (s, 6H), 19 F-NMR (DMSO-de) □ -112 46 (m, IF), MS (CI) m/z 352 ([M+H] + , 78%), 350 ([M+H] + , 75%), Anal Calc For C 16 H 13 BrFNO 2 C, 54 88, H, 3 74, N, 4 00 Found C, 54 83, H, 3 82, N, 3 95 The title compound was prepared, accordmg to the procedure of Example 16 startmg with 6-(3-bromo-5-fluoro-phenyl)-4,4-dimethyl-l,4-dihydro- benzo[d][l,3]oxazιn-2-one, as a yellow solid mp 221-222°C, Η-NMR (CDC1 3 ) δ 9 28 (s, IH), 7 49-7 45 (m, 2H), 7 30 (d, IH, J= 1 71 Hz), 7 24 (t, IH, J- 2 07 Hz), 7 17 (dt. IH, J= 9 54, 1 99 Hz), 6 93 (d, IH, J -= 8 25 Hz), 1 8 (s, 6H), MS (ES) m/z 364/366 ([M- H] ) EXAMPLE 56 5-(4,4-Dimethyl-2-thioxo-l,4-dihvdro-2H-3,l-benzoxazin-6-yl) thiophene-2- carbonitrile 5-(4,4-Dιmethyl-2-oxo- 1 , 4-dιhydro-2H-benzo [d] [ 1 ,3] oxazιn-6-yl)-thιophene- 2-carbonιtnle was prepared, accordmg to the procedure of Example 5 usmg 5-bromo- 2-thιophenecarbomtπle and (1 ,4-dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxazm-6- yl)boromc acid, as an off-white sohd mp 264-266 °C, Η-NMR (DMSO-de) δ 10 3 (s, IH), 7 97 (d, IH, J= 7 9 Hz), 7 60-7 66 (m, 3H), 6 96 (d, IH, J= 8 1 Hz), 1 65 (s, 6H), MS (APCI) m/z 285 (M+H) + , 302 (M+NH^ Anal Calc For Cι 5 H 12 N 2 0 2 S C, 63 36, H, 4 25, N, 9 85 Found C, 63 01, H, 4 36, N, 9 39 The title compound was prepared, accordmg to the procedure of Example 16 usmg 5-(4,4-dιmethyl-2-oxo- 1 ,4-dιhydro-2H-benzo [d] [1,3] oxazιn-6-yl)-thιophene-2- carbomtπle, as a yellow solid mp 242-244 °C, Η-NMR (CDC1 3 ) δ 9 05 (s, IH), 7 61 (d. IH, J= 3 89 Hz), 7 54 (dd, IH, J = 8 23, 1 56 Hz), 7 35 (m, IH), 7 24 (d, IH, J = 3 89 Hz), 6 88 (d, IH, J-= 8 26 Hz), 1 8 (s, 6H), MS (ES) m/z 299 ([M- H] ) EXAMPLE 57 3-Fluoro-5-(8-fluoro-4,4-dimethyl-2-thioxo-l,4-dihvdro-2H-3,l-benzoxazin-6- yl. benzonitrile V-(tert-Butoxycarbonylammo)-3-fluorobenzoιc acid (Takagishi et al Synlett 4, 360-2 (1992), mp 159-161 °C) was deprotected usmg tπfluoroacetic acid to give o- ammo benzoic acid, which was then treated with methylmagnesium bromide to afford o-aπnno dimethyl carbmol The o-amino dimethyl carbmol (2 23 g, 13 2 mmol) was treated with 1,1 -carbonyldiimidizole (2 8 g, 17 2 mmol) in THF (20 mL) at 50 °C for 12 hours The solution was then cooled to room temperature and ethyl acetate (100 mL) was added The organic layer was washed with 10% aqueous HCl solution (2x25 mL), dned over MgSO and concentrated The residue was puπfied via chromatography (sihca gel, 10% ethyl acetate/hexane) to give 8-fluoro-4,4-dιmethyl- dιhydro-benzo[d][l,3]oxazιn-2-one as a white sohd (1 3 g, 50%) mp 127-128 °C, Η- NMR (DMSO-de) δ 10 4 (s, IH), 7 22-7 12 (m, 2H), 7 07-7 00 (m, 2H), 1 6 (s, 6H), MS (APCI) m/z 196 ([M + H] + , 100%), Anal Calc For C 10 H 10 FNO 2 C, 61 53, H, 5 16, N, 7 18 Found C, 61 27, H, 5 37, N, 7 02 8-Fluoro-( 1 ,4-dihydro-4,4-dimethyl-2-oxo-2H-3 , 1 -benzoxιn-6-yl)boronιc acid was prepared from 6-bromo-8-Fluoro-4,4-dιmethyl-dιhydro-benzo[d][l,3]oxazm-2- one usmg the procedure of Example 4 3-Fluoro-5-(8-f-uoro-4,4-dιmethyl-2-oxo- 1 ,4-dιhydro-2H- benzo[d][l,3]oxazm-6-yl)-benzonιtnle was prepared, from 8-fluoro-(l,4-dιhydro-4,4- dιmethyl-2-oxo-2H-3,l-benzoxιn-6-yl)boronιc acid and 5-bromo-3-fluorobenzonιtπle accordmg to the procedure of example 5, as a white sohd mp 256-257 °C, Η-NMR (DMSO-de) δ 10 5 (s, IH), 8 20 (bs, IH), 8 06 (dt, IH, J = 10 48, 2 16 Hz), 7 85-7 82 (m, IH), 7 77 (dd, IH, J = 11 89, 1 81 Hz), 7 63 (s, IH), 1 7 (s, 6H), MS (El) m/z 314(^, 60%) The title compound was prepared, accordmg to the procedure of Example 16 usmg 3-Fluoro-5-(8-fluoro-4,4-dιmethyl-2-oxo- 1 ,4-dιhydro-2H-benzo[d] [ 1 ,3] oxazin- 6-yl)-benzoratπle, as a yellow solid Η-NMR (CDC1 3 ) δ 8 91 (s, IH), 7 61 (d, IH), 7 47 (dt, IH, J= 9 25, 2 0 Hz), 7 39 (m, IH), 7 33-7 29 (m, IH), 7 13 (s, IH), 1 8 (s, 6H) EXAMPLE 58 3-(l,2-Dihvdro-2-thioxospiro[4H-3,l-benzoxaane-4,l-cyclohexan1-6- vDbenzonitrile 3-(l,2-Dιhydro-2-oxospιro[4H-3,l-benzoxazme-4,l-cyclohexan]-6-yl)- benzonitπle was prepared, accordmg to Procedure B from spιro-(4, l '-cyclohexane- l,4-dιhydro-2-oxo-2H-3,l-benzoxazm-6-yl) boromc acid and 3-bromobenzomtnle, as a tan powder mp 245-247 °C, Η-NMR(DMSO-d 6 ) δ 10 31 (s, IH), 8 21 (s, IH), 8 02 (d, IH, J= 8 0 Hz), 7 78 (d, IH, J = 7 7 Hz), 7 68-7 61 (m, 3H), 6 97 (d, IH, J = 8 2 Hz), 1 98-1 96 (m, 4H), 1 75-1 64 (m, 5H), 1 40-1 32 (m, IH), MS (El) m/z 318PVT], Anal Calc For C 20 H 18 N 2 O 2 1/2 H 2 O C 73 38, H, 5 85, N, 8 56 Found C, 73 86, H, 5 81, N, 8 22 The title compound was prepared, accordmg to the procedure of Example 16 startmg with 3-( 1 ,2-dιhydro-2-oxospιro [4H-3, 1 -benzoxazιne-4, 1 -cyclohexan] -6- yl)benzonιtπle, as a white sohd mp 222-224°C, Η-NMR (CDC1 3 ) δ 9 08 (s, IH), 7 86-7 81 (m, IH), 7 77(dt, IH, J= 7 79, 1 35 Hz), 7 67-7 64 (m, IH), 7 58 (d, IH, J - 7 77 Hz), 7 48 (dd, IH, J= 8 2, 1 93 Hz), 7 35 (d, IH, J = 1 78 Hz), 6 91 (d, IH, J = 8 2 Hz), 2 30-2 26 (m, 2H), 2 07-1 98 (m, 2H), 1 90-1 70 (m, 4H), 1,39-1 24 (m, 2H), MS (ES) m/z 333 ([M-H] ) EXAMPLE 59 5-(l,2-Dihvdro-2-thioxospiro.4H-34-benzoxa-rine-4.1-cvclohexanl-6-yl)-4- methyl-2-thiophenecarbonitrile 5-( 1 , 2-Dιhydro-2-oxospιro [4H-3 , 1 -benzoxazιne-4, 1 -cyclohexan] -6-yl)-4- methyl-2-thιophenecabonιtπle was prepared, accordmg to Procedure B from sprro-(4, 1 '-cyclohexane- l,4-dιhydro-2-oxo-2H-3,l-benzoxazιn-6-yl) boronic acid and 2-bromo- 3-methyl-5-cyanothιophene, as a white powder mp 200-203 °C, Η-NMR (DMSO-de) δ 10 4 (s, IH), 7 85 (s, IH), 7 43-7 40 (m, 2H), 7 0 (d, IH, J= 8 8 Hz), 2 27 (s,3 H), 2 00-1 62 (m, 9H), 1 42-1 23 (m, IH), MS(EI) m/z 338 (M"), Anal Calc For C, 9 H 18 N 2 0 2 S C, 67 43, H, 5 36, N, 8 28 Found C, 67 12, H, 5 45, N, 8 05 The title compound was prepared, accordmg to the procedure for Example 16 startmg with 5-( 1 ,2-Dιhydro-2-oxospιro [4H-3 , 1 -benzoxazιne-4, 1 -cyclohexan]-6-yl)-4- methyl-2-thιophenecarbonιtπle, as a yellow sohd mp 199-201°C, Η-NMR (CDC1 3 ) δ 8 92 (s, IH), 7 5 (s, IH), 7 36 (dd, IH, J= 8 17, 1 9 Hz), 7 23 (d, IH, J= 1 7 Hz), 6 87 (d, IH, J= 8 18 Hz), 2 3 (s, 3H), 2 05-1 70 (m, 7H), 1 36-1 25 (m, 3H). MS (ES) m/z 353 ([M-H] ) EXAMPLE 60 5-(l,2-Dihydro-2-thioxospirof4H-3,l-benzoxazine-4,l-cvclohexanl-6-yl)-2- thiophenecarbonitrile 5-(l, 2-Dιhydro-2-oxospιro[4H-3, l-benzoxazιne-4, 1 -cyclohexan] -6-yl)-2- thiophenecarbomtnle was prepared, accordmg to Procedure B from spιro-(4, 1 '- cyclohexane-l,4-dιhydro-2-oxo-2H-3,l-benzoxazm-6-yl) boronic acid and 2-bromo-5- cyanothiophene, as a tan powder mp 243-245 °C, Η-NMR (DMSO-de) δ 10 41(s, IH), 7 98-7 97 (d, IH, J = 3 9 Hz), 7 67-7 60 (m, 3H), 6 97-6 94 (d, IH, J = 8 3 Hz), 1 98-1 92 (m, 4H), 1 74-1 64 (m, 5H), 1 45-1 21 (m, IH), MS (El) m/z 324 (IvT) Anal Calc For C 18 H 16 N 2 0 2 S 1/2 H 2 O C, 65 08, H, 5 04, N, 8 18 Found C, 64 84, H, 5 09, N,8 40 The title compound was prepared, accordmg to the procedure for Example 16 startmg with 5-(l,2-Dιhydro-2-oxospιro[4H-3,l-benzoxazme-4,l-cyclohexan]-6-yl)-2- thiophenecarbonitπle, as a yellow sohd mp 232-233 °C, Η-NMR (CDC1 3 ) δ 8 90 (s, IH), 7 6 (d, IH, J= 3 93 Hz), 7 36 (d, IH, J= 1 8 Hz), 7 24-7 20 (m, IH), 6 85 (d, IH, J= 8 25 Hz), 2 28-2 23 (m, 2H), 2 11-1 96 (m, 2H), 1 90-1 70 (m, 5H), 1 38-1 33 ( , 2H), MS (ES) m/z 339 ([M-H] ) EXAMPLE 61 6-(3-Chloro-4-fluorophenyl)-4,4-dimethyl-l,4-dihydro-2H-3,l-benzoxazine-2- thione 6-(3-Chloro-4-fluoro-phenyl)-4.4-dιmethyl-l,4-dιhydro-benzo[d][l,3]oxazm-2- one was prepared, from 6-bromo-4,4-drmethyl-l,4-dihydro-benzo[d][l,3]oxazm-2-one and l-bromo-3-chloro-4-fluorobenzene accordmg to Procedure A, as a white sohd mp 211-212 °C; Η-NMR (DMSO-de) δ 10.4 (s, IH), 7.92 (dd, IH, J = 7.13, 2.19 Hz), 7.71-7.66 (m, IH), 7.60-7.57 (m, 2H), 7.49 (t, 1H, J= 8.95 Hz), 6.96 (d, 1H, J = 8.01 Hz), 1.67 (s, 6H); MS (El) m/z 305 ([M + H] + , 20%); Anal. Calc. For C, 6 H 13 ClFNO 2 : C, 62.86, H, 4.29, N, 4.58. Found: C, 62.52, H, 4.45, N, 4.42. The title compound was prepared, according to the procedure for Example 16 starting with 6-(3-Chloro-4-fluoro-phenyl)-4,4-dimethyl-l,4-dihydro- benzo[d][l,3]oxazin-2-one, as a white solid: mp 196-197 °C; ! H-NMR (CDC1 3 ) δ 9.29 (s, IH), 7.55 (dd, 1H, J = 6.89, 2.28 Hz), 7.45 (dd, 1H, J = 8.21, 1.91 Hz), 7.41-7.27 (m, IH), 7.28-7.27 ( , IH), 7.22 (t, 1H, J= 8.66 Hz), 6.92 (d, 1H, J = 8.22 Hz), 1.81 (s, 6H); MS (ES) m/z 320 ([M-H] " ). EXAMPLE 62 5-(4,4-DimethyI-2-thioxo- 1 ,4-dihyd ro-2H-3, l-benzoxazin-6-v-)-4- propylthiophene-2-carbonitrile 5-(4,4-Dimethyl-2-oxo- 1 ,4-dihydro-2H-benzo[d] [ 1 ,3] oxazin-6-yl)-4-/. -propyl- thiophene-2-carbonitrile was prepared according to Procedure B from spiro-(4, 1'- cyclohexane-l,4-dihydro-2-oxo-2H-3,l-benzoxazin-6-yl) boronic acid and 2-bromo-3-«- propyl-5-thiophenecarbonitrile. White crystals: mp 160-162 °C; IR (KBr) 2220 cm "1 ; Η-NMR (DMSO-de) δ 10.47 (s, IH), 7.93 (s, IH), 7.38-7.36 (m, 2H), 7.01 (d, IH, J = 8.7 Hz), 2.59-2.48 (m, 2H), 1.64-1.51 (m, 2H), 0.85 (t, 3H, J= 7.3 Hz). MS(-ESI) m/z [M-H] " 325; Anal. Calc. For Cι 8 H 18 N 2 0 2 S-3/4H 2 O: C, 63.60; H, 5.78, N, 8.24. Found: C, 63.48; H, 5.59; N, 8.04. The title compound was prepared according to the procedure for Example 16 starting with 5-(4,4-Dimethyl-2-oxo-l,4-dihydro-2H-benzo[d][l,3]oxazin-6-yl)-4- propyl-thiophene-2-carbonitrile. A yellow solid: mp 174-175°C; 1 H-NMR (CDC1 3 ) δ 9.43 (s, IH), 7.49 (s, IH), 7.35 (dd, IH, .7 = 8.17, 1.8 Hz), 7.19 (d, IH, J= 1.62 Hz), 6.95 (d, IH, J= 8.18 Hz), 2.56 (t, 2H, J = 7.53 Hz), 1.79 (s, 6H), 1.60 (m, 2H, J = 7.56 Hz), 0.92 (t, 3H, J =7.3 Hz); MS (ES) m/z 341 ([M-H] ). EXAMPLE 63 4-.4,4-Dimethyl-2-thioxo-L4-dihydro-2H-3,l-benzoxazin-6-yl)-2-furonitrile 4-(4,4-Dιmethyl-2-oxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6-yl)-furan-2- carbonitπle was prepared from (l,4-dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxazιn- 6-yl)boromc acid and 4-bromo-2-furancarbonιtπle accordmg to Procedure B Off- white sohd mp 255-256 °C Η-NMR (DMSO-de) δ 10 32 (s, IH, D 2 0 exchangeable), 8 57 (s, IH), 8 15 (s, IH), 7 61 (s, IH), 7 55 (dd, IH, J= 8 3, 1 5 Hz), 6 92 (d, IH, J= 8 2 Hz), 1 65 (s, 6H), MS (ESI) m/z 269( M+H, 72%) Anal Calc For C, 5 H, 2 N 2 O 3 C, 67 16, H, 4 51, N, 10 44 Found C, 67 14, H, 4 59, N, 10 07 The title compound was prepared accordmg to the procedure for Example 16 startmg with 4-(4,4-dιmethyl-2-oxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6-yl)-fur an- 2-carbonιtπle An off-white sohd mp 214-216°C, Η-NMR (CDC1 3 ) δ 8 93 (s, IH), 7 83 (s, IH), 7 39 (dd, IH, J = 8 2, 1 87 Hz), 7 35 (s, IH), 7 22-7 21 (m, IH), 6 86 (d, IH. J= 8 2 Hz), 1 79 (s, 6H), MS (ES) m/z 283 ([M-H] ) EXAMPLE 64 4-Butyl-5-(4,4-dimethyl-2-thioxo-l,4-dihvdro-2H-3,l-benzoxazin-6-yl)thiophene- 2-carbonitrile 5-(4,4-Dιmethyl-2-oxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6-yl)-4-n-butyl- thιophene-2-carbomtnle was prepared accordmg to Procedure B from spιro-(4, 1'- cyclohexane-l,4-dιhydro-2-oxo-2H-3,l-benzoxazm-6-yl) boronic acid and 2-bromo-3-n- butyl-5-thιophenecarbomtπle White crystals mp 167-168 °C, 1 H-NMR (DMSO-d 6 ) δ 1046 (s, IH), 7 93 (s, IH), 7 38-7 36 ( , 2H), 7 01 (d, IH, J= 8 7 Hz), 2 59 (t, 2H, J = 8 1 Hz), 1 63 (s, 6H), 1 58-1 51 (m, 2H), 1 48-1 17 (m, 2H), 0 82 (t, 3H, J= 7 4 Hz) MS(-ESI) m/z [M-H] " 339 Anal Calc For Cι 9 H 20 N 2 O 2 S- 1/4 H 2 O C, 66 16, H, 5 99, N, 8 12 Found C, 66 33, H, 5 92, N, 7 85 The title compound was prepared accordmg to the procedure for Example 16 startmg with 4-Butyl-5-(4,4-dιmethyl-2-oxo- 1 ,4-dιhydro-2H-benzo [d] [ 1 ,3] oxazm-6- yl)-thιophene-2-carbomtπle A yellow solid mp 174-175°C, ! H-NMR (CDC1 3 ) δ 9 58 (s, IH), 7 50 (s, IH), 7 35 (dd, IH, J = 8 19, 1 84 Hz), 7 19 (d, IH, J= 1 7 Hz), 6 96 (d, IH, J= 8 18 Hz), 2 58 (t, 2H, J= 7 61 Hz). 1 80 (s, 6H), 1 61- 1 54 (m, 2H), 1 35-1 25 ( , 2H), 0 88 (t, 3H, J= 7 29 Hz). MS (ES) m/z 355 ([M-H] ) EXAMPLE 65 6-(3-Bromophenyl)-4,4-dimethyl-l,4-dihydro-2H-3,l-benzoxazine-2-thione 6-(3-Bromo-phenyl)-4,4-dιmethyl- 1 ,4-dιhydro-benzo [d] [ 1 ,3] oxazm-2-one was prepared from (l,4-dιhydro-4,4-dιmethyl-2-oxo-2H-3,l-benzoxm-6-yl)boromc acid and 1,3-dιbromobenzene accordmg to procedure B A white sohd mp 174-175 °C, 'H-NMR (DMSO-de) δ 10 35 (s, IH), 7 88 (bs, IH), 7 68 (d, IH, J= 7 5 Hz), 7 6- 7 51 (m, 3H), 7 4 (t, IH, J = 7 5 Hz), 6 97 (d, IH, J = 8 57 Hz), 1 64 (s, 6H), MS (El) m z 331([M t ], 60%), 333([Mi, 60%), Anal Calc For C, 6 Hι 4 BrNO 2 C, 57 85, H, 4 25, N, 4 22 Found C, 57 7, H, 4 36, N, 4 09 A mixture of 6-(3-bromo-phenyl)-4,4-dιmethyl-l,4-dιhydro- benzo[d][l,3]oxazιn-2-one (3 g, 9 04 mmol) and Lawesson's Reagent (1 83 g, 4 51 mmol) m toluene (30 mL) was heated to 110°C for 24 hours The reaction was cooled, the toluene removed in vacuo and the residue punfied via flash chromatography (sihca gel, 20% ethyl acetate/hexane) to give 6-(3-bromophenyl)-4,4- dιmethyl-l,4-dιhydro-2H-3,l-benzoxazme-2-thιone (1 93 g, 61%) as a yellow sohd mp 191-193°C, 'H-NMR (DMSO-d6) δ 12 3 (s, IH), 7 92 (s, IH), 7 72-7 65 (m, 3H), 7 57-7 54 (m, IH), 7 45-7 39 (m, IH), 7 14-7 11 (m, IH), 1 7 (s, 6H), MS (ES) m/z 347 ([M-H] , 100%), Anal Calc For C 16 H, 4 BrNOS C, 55 18, H, 4 05, N, 4 02 Found C, 55 17. H, 3 93, N, 3 97 EXAMPLE 66 2-(4,4-Dimethyl-2-thioxo-l,4-dihydro-2H-3,l-benzoxazin-6-yl)thiophene-3- carbonitrile 2-(4,4-Dιmethyl-2-oxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6-yl)-tmophene- 3-carbonιtnle was prepared accordmg to procedure B from (l,4-dιhydro-4,4-dιrnethyl- 2-oxo-2H-3,l-benzoxιn-6-yl)boronιc acid and 2-bromo-3-thιophenecarbomtπle An off-white sohd mp 200-202 °C, ! H-NMR (DMSO-de) δ 10 49 (s, IH), 7 75(ιa 1H),7 63(d, IH, J = 2 2 Hz), 7 59 (m, IH), 7 50 (m, IH), 7 02 (d, IH, J = 8 1 Hz), 1 63(s, 6H), MS(-ESI) m/z 283 (M-H) The title compound was prepared accordmg to the procedure for Example 16 startmg with 2-(4,4-Dιmethyl-2-oxo-l,4-dιhydro-2H-benzo[d][l,3]oxazm-6-yl)- thιophene-3-carbomtπle A yellow solid mp 194-195°C, ] H-NMR (CDC1 3 ) δ 9 56 (s, IH), 7 67-7 62 (m, 2H), 7 35 (d, IH, J = 5 39 Hz), 7 30 (d, IH, J= 5 33 Hz), 6 98 (d, IH, J= 8 18 Hz), 1 80 (s, 6H), MS (ES) m/z 299 ([M-H] ) All publications cited in this specification are incorporated herem by reference herem While the mvention has been descnbed with reference to a particularly prefeπed embodiment, it will be appreciated that modifications can be made without departing from the spiπt of the mvention Such modifications are mtended to fall withm the scope of the appended claims

Claims: What is Claimed: 1 A compound of the formula wherem Ri and R are mdependent substituents selected from the group of H, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 2 to Ce alkenyl, substituted C 2 to C 6 alkenyl, C 2 to C 6 alkynyl, substituted C 2 to C 6 alkynyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocychc, COR A , or NR B COR A , or R 1 and R 2 are fused to form a spirocychc rmg selected from a), b) or c), below, each spirocychc rmg bemg optionally substituted by from 1 to 3 substituents selected fromH or G-C 3 alkyl a) a 3 to 8 membered spirocychc alkyl πng, preferably a 3 to 6 membered spirocyc c alkyl rmg, or b) a 3 to 8 membered spirocychc alkenyl πng, preferably a 3 to 6 membered spirocychc alkenyl πng, or c) a 3 to 8 membered spirocychc πng containmg one to three heteroatoms selected from O, S and N, preferably a 3 to 6 membered spirocychc rmg containmg one to three heteroatoms, R A is selected from H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, ammo, G to C 3 ammoalkyl, or substituted G to C 3 ammoalkyl, R B is H, Ci to C 3 alkyl, or substituted Ci to C 3 alkyl, R 3 is H, OH, NH 2 , Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 6 alkenyl, substituted G to C 6 alkenyl, alkynyl, or substituted alkynyl, or COR c , R c is selected from H, Ci to C 3 alkyl, substituted G to C 3 alkyl, aryl, substituted aryl, G to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 ammoalkyl, or substituted Ci to C 3 ammoalkyl, R 4 is selected from H, halogen, CN, NO 2 , Ci to Ce alkyl, substituted G to C 6 alkyl, Ci to C 6 alkoxy, substituted G to C 6 alkoxy, Ci to C 6 ammoalkyl, or substituted Ci to C 6 ammoalkyl, R 5 is selected from groups a), b), or c) below a) R 5 is a trisubstituted benzene rmg containmg the substituents X, Y and Z as shown below X is selected from the group mcludmg halogen, CN, G to C 3 alkyl, substituted Ci to C 3 alkyl, G to C 3 alkoxy, substituted G to C 3 alkoxy, G to C 3 thioalkoxy, substituted Ci to C 3 thioalkoxy, Ci to C 3 ammoalkyl, substituted G to C 3 ammoalkyl, N0 2 , Ci to C 3 perfluoroalkyl, 5 or 6 membered heterocychc rmg containmg 1 to 3 heteroatoms, COR D , OCOR D , orNR E COR D , R D is H, Ci to C 3 alkyl, substituted G to C 3 alkyl, aryl, substituted aryl, G to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 ammoalkyl, or substituted Q to C 3 ammoalkyl, R E is H, Ci to C 3 alkyl, or substituted G to C 3 alkyl, Y and Z are mdependent substituents selected from the group of H, halogen, CN, NO 2 , Ci to C 3 alkoxy, G to C 3 alkyl, or Q to C 3 thioalkoxy, or b) R 5 is a five or six membered heterocyclic πng with 1, 2, or 3 πng heteroatoms selected from the group of O, S, S(O), S(0 2 ) or NR 6 and containmg one or two mdependent substituents from the group of H, halogen, CN, NO 2 and Ci to C 3 alkyl, G to C 3 alkoxy, G to C 3 ammoalkyl, COR F , or NR G COR F , R F is H, Ci to C 3 alkyl, substituted Ci to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 ammoalkyl, or substituted G to C 3 ammoalkyl, R G is H, C, to C 3 alkyl, or substituted G to C 3 alkyl, R 6 is H, or Ci to C 3 alkyl, or c) or R 5 is a six membered rmg with the structure wherem X 2 is halogen, CN, or N0 2 Q 1 is S, NR 7 , or CR 8 R 9 ; R 7 is selected from the group of CN, G to C 6 alkyl, substituted G to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocyclic, or substituted heterocyclic, SO 2 CF 3 , OR 11 or NR U R 12 ; R 8 and R 9 are independent substituents selected from the group of H, Ci to C 6 alkyl, substituted G to Cβ alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, NO 2 , CN, or CO 2 R 10 ; R 10 is C, to C 3 alkyl; or CR 8 R 9 comprise a six membered ring as shown by the structure below: Q is selected from the moieties: — N— O-R 12 , -,» or — O— N— R 13 . R 11 , R 12 and R 13 are independently selected fromH, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl or sulfonyl; or a pharmaceutically acceptable salt thereof. 2. A compound of Claim 1 having the structure: wherem R 1 is H, Ci to C 6 alkyl, substituted G to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocyclic, COR A , or NR B COR A , R 2 is H, Ci to C 6 alkyl, substituted Ci to C 6 alkyl, C 2 to C 6 alkenyl, substituted C 2 to C 6 alkenyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocyclic, COR A , or NR B COR A , or R 1 and R 2 are fused to form a spirocychc rmg selected from a), b) or c), below, each spirocychc rmg bemg optionally substituted by from 1 to 3 substituents selected fromH or Q-C 3 alkyl a) a 3 to 8 membered spirocychc alkyl πng, preferably a 3 to 6 membered spirocychc alkyl rmg, or b) a 3 to 8 membered spirocychc alkenyl rmg, preferably a 3 to 6 membered spirocychc alkenyl πng, or c) a 3 to 8 membered spirocychc πng containmg one to three heteroatoms selected from O, S and N, preferably a 3 to 6 membered spirocychc rmg containmg one to three heteroatoms, R A is H, Ci to C 3 alkyl, substituted G to C 3 alkyl, aryl, substituted aryl, G to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 ammoalkyl, or substituted Q to C 3 ammoalkyl, R B is H, Ci to C 3 alkyl, or substituted C, to C 3 alkyl; R 3 is H, OH, NH 2 , G to C 6 alkyl, substituted C, to C 6 alkyl, C 3 to C 6 alkenyl, substituted G to Cβ alkenyl, alkynyl, or substituted alkynyl, or COR c ; R c is H, Ci to C 4 alkyl, substituted Ci to C 4 alkyl, aryl, substituted aryl, G to C 4 alkoxy, substituted G to C alkoxy, Ci to C aminoalkyl, or substituted G to C 4 aminoalkyl; R 4 is H, halogen, CN, N0 2 , G to C 6 alkyl, substituted G to C 6 alkyl, C, to Ce alkoxy, substituted Ci to C 6 alkoxy, Ci to C 6 aminoalkyl, or substituted Ci to C 6 aminoalkyl; R 5 is a trisubstituted benzene ring containing the substituents X, Y and Z as shown below, X is taken from the group including halogen, CN, G to C 3 alkyl, substituted G to C 3 alkyl, G to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 thioalkoxy, substituted G to C 3 thioalkoxy, Ci to C 3 aminoalkyl, substituted Ci to C 3 aminoalkyl, N0 2 , Ci to C 3 perfluoroalkyl, 5 membered heterocychc ring containing 1 to 3 heteroatoms, COR D , OCOR D , or NR E COR D ; R D is H, Ci to C 3 alkyl, substituted G to C 3 alkyl, aryl, substituted aryl, Ci to C 3 alkoxy, substituted Ci to C 3 alkoxy, Ci to C 3 aminoalkyl, or substituted Ci to C 3 aminoalkyl; R E is H, C, to C 3 alkyl, or substituted G to C 3 alkyl, Y and Z are mdependent substituents taken from the group of H, halogen, CN, NO 2 , Ci to C 3 alkoxy, Ci to C 3 alkyl, or Ci to C 3 thioalkoxy, or R 5 is a five or six membered rmg with 1, 2, or 3 heteroatoms from the group mcludmg O, S, SO, S0 2 or NR 6 and containmg one or two mdependent substituents from the group mcludmg H, halogen, CN, N0 2 and G to C 3 alkyl, G to C 3 alkoxy, R 6 is H, or Ci to C 3 alkyl, R 7 is selected from CN, G to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, orSO 2 CF 3 , R 8 and R 9 are mdependent substituents from the group mcludmg H, G to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, N0 2 , CN CO 2 R 10 , R 10 is C, to C 3 alkyl, or CR 8 R 9 compπse a six membered πng as shown by the structure below or a pharmaceutically acceptable salt thereof 3 A compound of Claim 2 havmg the structure R 1 and R 2 and are independently selected from the group of Ci to C 3 alkyl, substituted G to C 3 alkyl, or spirocyclic alkyl constructed by fusing R 1 and R 2 to form a 3 to 6 membered spirocychc ring; is H, OH, NH 2 , C, to C 6 alkyl, substituted G to C 6 alkyl, or COR c R c is H, Ci to C 4 alkyl, or Ci to C alkoxy; R 4 is H, halogen, N0 2 , Ci to C 3 alkyl, or substituted Ci to C 3 alkyl; X is selected from the group of halogen, CN, G to C 3 alkoxy, Ci to C 3 alkyl, N0 2 , Ci to C 3 perfluoroalkyl, 5 membered heterocyclic ring containing 1 to 3 heteroatoms, or G to C 3 thioalkoxy; Y is a substituent selected from the group of H, halogen, CN, NO 2 , Ci to C 3 alkoxy, Ci to C alkyl, or Ci to C 3 thioalkoxy; Q 1 is S, NR 7 , or CR 8 R 9 ; R 7 is selected from the group of CN, G to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to Cs cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, or S0 2 CF 3 , R 8 and R 9 are mdependent substituents selected from the group of H, G to C 6 alkyl, substituted G to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, N0 2 , CN or C0 2 R 10 , R 10 is Ci to C 3 alkyl, or CR S R 9 compπses a six membered πng as shown by the structure below or a pharmaceutically acceptable salts thereof 4 A compound of Claim 2 having the structure R 1 and R 2 and are mdependently selected from the group of Ci to C 3 alkyl, substituted G to C 3 alkyl, or spirocychc alkyl constructed by fusmg R 1 and R 2 to form a 3 to 6 membered spirocychc rmg, R is H, OH, NH 2 , Ci to Ce alkyl, substituted C, to C 6 alkyl, or COR c , R c is H, Ci to C 4 alkyl, or G to C 4 alkoxy, R 4 is H, halogen, N0 2 , C, to C 3 alkyl, or substituted G to C 3 alkyl, X is selected from the group of halogen, CN, G to C 3 alkoxy, Ci to C 3 alkyl, N0 2 , Ci to C 3 perfluoroalkyl, 5 membered heterocychc rmg containmg 1 to 3 heteroatoms, or Ci to C 3 thioalkoxy, Y is a substituent selected from the group of H, halogen, CN, NO 2 , Ci to C 3 alkoxy, Ci to C 4 alkyl, or Ci to C 3 thioalkoxy, R 6 is H, or Ci to C 3 alkyl, or Ci to C 4 CO 2 alkyl, Q is S, NR 7 , or CR 8 R 9 , R 7 is selected from the group of CN, G to C 6 alkyl, substituted Ci to C 6 alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc. substituted heterocychc, or S0 2 CF 3 , R 8 and R 9 are mdependent substituents selected from the group of H, Ci to C 6 alkyl, substituted Ci to Ce alkyl, C 3 to C 8 cycloalkyl, substituted C 3 to C 8 cycloalkyl, aryl, substituted aryl, heterocychc, substituted heterocychc, NO , CN or CO 2 R 10 , R 10 is C, to C 3 alkyl, or CR 8 R 9 together compnses a six membered rmg of the structure or a pharmaceutically acceptable salts thereof. A compound of Claim 2 having the formula: wherein: R 1 and R 2 and are independently selected from the group of Ci to C 3 alkyl or substituted Ci to C 3 alkyl, or R 1 and R 2 are fused to form a 3 to 6 membered spirocychc alkyl ring; R 3 is H, OH, NH 2 , C, to C 6 alkyl, substituted C, to C 6 alkyl, or COR c ; R c is H, Ci to C 4 alkyl, or Ci to C 4 alkoxy; R 4 is H, halogen, NO 2 , Ci to C 3 alkyl, or substituted Ci to C 3 alkyl; X 1 is N or CX 2 ; X 2 is halogen, CN, or N0 2 ; and Q is S, NR 7 , or CR 8 R 9 or a pharmaceutically acceptable salt thereof 6 A compound of Claim 1 which is 6-(3-Chlorophenyl)-4,4-drmethyl-l,4- dιhydro-benzo[d][l,3]oxazm-2-thιone or a pharmaceutically acceptable salt thereof 7 A compound of Claim 1 which is 4-(4,4-Dιmethyl-2-thιoxo-l,4- dιhydro-2H-benzo[d][l,3]oxazm-6-yl)-thιophene-2-carbomtπle or a pharmaceutically acceptable salt thereof 8 A compound of Claim 1 which is 6-Bromo-4,4-dιmethyl-l,4-dιhydro- benzo[d][l,3]oxazιn-2-thιone or a pharmaceutically acceptable salt thereof 9 A compound of Claim 1 which is 3-(4,4-Dιmethyl-2-thιoxo-l,4- dihydro-2H-benzo[d][l,3]oxazm-6-yl)-5-fluorobenzonitnle or a pharmaceutically acceptable salt thereof 10 A compound of Claim 1 which is 3-(4,4-Dιmethyl-2-thιoxo- 1 ,4- dιhydro-2H-benzo[d][l,3]oxazm-6-yl)-benzonιtnle or a pharmaceutically acceptable salt thereof 11 A method of mducmg contraception m a mammal, the method compπsmg admimsteπng to a mammal m need thereof a compound of Claim 1, or a pharmaceutically acceptable salt thereof 12 A pharmaceutical composition compnsmg a pharmaceutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable earner or excipient

Inventors: FENSOME ANDREW, JONES TODD K, MARSCHKE KEITH B, TEGLEY CHRISTOPHER M, TEREFENKO EUGENE A, ZHANG PUWEN, ZHI LIN, FENSOME, ANDREW, JONES, TODD, K., MARSCHKE, KEITH, B., TEGLEY, CHRISTOPHER, M., TEREFENKO, EUGENE, A., ZHANG, PUWEN, ZHI, LIN
Applicants: AMERICAN HOME PROD, FENSOME ANDREW, JONES TODD K, LIGAND PHARM INC, MARSCHKE KEITH B, TEGLEY CHRISTOPHER M, TEREFENKO EUGENE A, ZHANG PUWEN, ZHI LIN, AMERICAN HOME PRODUCTS CORPORATION, FENSOME, ANDREW, JONES, TODD, K., LIGAND PHARMACEUTICALS, INC., MARSCHKE, KEITH, B., TEGLEY, CHRISTOPHER, M., TEREFENKO, EUGENE, A., ZHANG, PUWEN, ZHI, LIN
Application year: 2000
Main classification: C07D265
IPC codes: A61P15, A61P35, C07D265, C07D413